Compound

all-cis-docosa-4,7,10,13,16,19-hexaenoic acid

C22-unsaturated fatty acids found predominantly in fish oils.

Definition from MeSH (D004281), National Library of Medicine, read 2026-09-23. NLM revises MeSH; this copy may not reflect its current record.

CHEBI:28125ChEBI

Open in the graph

Studied for

10 endpoints · 7 findings · 9 papers · 1 null

Adverse event occurrence (oral or enteral supplement)no detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Necrotising enterocolitis incidencelowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Birth weightraisesEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
TriglycerideslowersEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
Tumour necrosis factor alpha concentrationraisesEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.

All 7 endpoints, with the quotes

Structure

A docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19.

2D depiction · 3D model shown

Loading the model…

A generated conformer of all-cis-docosa-4,7,10,13,16,19-hexaenoic acid — one low-energy arrangement PubChem computed, not a measured structure. Hydrogens are not drawn; the formula counts them.

Class: Organic compound
Formula: C22H32O2
Mass: 328.496 g/mol
Charge: 0
InChIKey: MBMBGCFOFBJSGT-KUBAVDMBSA-N
SMILES: CC/C=CC/C=CC/C=CC/C=CC/C=CC/C=CCCC(=O)O
Look it up: ChEBI PubChem By InChIKey

Identity from ChEBI, geometry from PubChem. Not evidence.

What the evidence says

How to read these marks

10 findings · 10 endpoints · 9 papers · 1 null · by evidence strength

Heavier lines are better evidence, and a line with a gap in the middle is an inference rather than a reported result. Two lines arriving at one endpoint are two findings of it, marked ×2. How evidence strength is computed.

What moved

9 findings

Decreases necrotising enterocolitis incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Confirmed NEC was lower in infants from the DHA-group compared with the control-group (0/100 vs. 7/100, p = 0.007) with a RR of 0.93 (95% CI 0.881 to 0.981, p = 0.008); there was a risk difference of −7% (95% CI −12.00 to −1.99), and a number needed to treat of 15 (95% CI 8.3 to 50).”
Quoted verbatim from Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial..
Study

RCT
Duration

14 days
Dose

75 mg DHA/kg body weight daily for 14 days from the first enteral feed
Population

Preterm infants (birthweight 1000-1500 g) dosed enterally by orogastric tube; outcome measured in the same infants; per-protocol analysis; confirmed NEC defined as Bell stage IIa or greater (modified Walsh)
Effect 0.93 risk ratio, 95% CI 0.881 to 0.981
Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial.2021PMID:33671220An author is affiliated with a producerPermalink
Increases birth weight
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“In contrast, prenatal DHA supplementation significantly increased neonatal birth weight (mean difference [MD] = 72.51 g, 95% CI: 37.55-107.48), whereas no notable improvements were observed in head circumference, gestational age, birth length, or any of the assessed neurodevelopmental outcomes.”
Quoted verbatim from Impact of Omega-3 Fatty Acid Docosahexaenoic Acid Supplementation in Individuals During Pregnancy on Neurodevelopment and Growth of Offspring: Systematic Review and Meta-Analysis..
Study

meta-analysis
Population

Pregnant women given prenatal DHA supplementation (meta-analysis pooling RCTs from 2001-2023, general population); birth weight measured in offspring
Effect 72.51 mean difference, 95% CI 37.55 to 107.48
Impact of Omega-3 Fatty Acid Docosahexaenoic Acid Supplementation in Individuals During Pregnancy on Neurodevelopment and Growth of Offspring: Systematic Review and Meta-Analysis.2026PMID:42494300Permalink
Decreases triglycerides
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“The results showed that both EPA and DHA were effective at lowering serum triglycerides (TG) levels.”
Quoted verbatim from Effects of dietary eicosapentaenoic acid and docosahexaenoic acid supplementation on metabolic syndrome: A systematic review and meta-analysis of data from 33 randomized controlled trials..
Study

meta-analysis
Population

Adults in 33 randomised controlled trials of pure eicosapentaenoic acid or pure docosahexaenoic acid preparations, pooled for features of the metabolic syndrome
Effects of dietary eicosapentaenoic acid and docosahexaenoic acid supplementation on metabolic syndrome: A systematic review and meta-analysis of data from 33 randomized controlled trials.2021PMID:34229258Permalink
Increases tumour necrosis factor alpha concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“DHA supplementation resulted in greater increases in the plasma cytokines IFN-γ and TNF-α compared to placebo (P-interaction < .05).”
Quoted verbatim from The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial..
Study

RCT
Duration

4 months
Dose

DHA-enriched algae, 4.4 g/day, 18 weeks
Population

women with breast cancer receiving neoadjuvant chemotherapy (both arms)
The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial.2025PMID:40651709Permalink
Accumulates in lung
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding
“Furthermore, dietary DHA increased pulmonary DHA and its oxylipins while decreasing proinflammatory omega-6 polyunsaturated fatty acids and their oxylipins.”
Quoted verbatim from Docosahexaenoic Acid and Its Metabolites Protect against Ozone-induced Pulmonary Inflammation..
Study

animal · not in humans
Duration

6 weeks
Dose

DHA-enriched diet, 2% kcal from DHA
Population

C57BL/6J mice fed a DHA-enriched diet (2% kcal from DHA) for 6 weeks, then exposed to ozone
Docosahexaenoic Acid and Its Metabolites Protect against Ozone-induced Pulmonary Inflammation.2025PMID:40208640Permalink
Is transported by MFSD2A
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding
“Unexpectedly, cell-based studies indicate that Mfsd2a transports DHA in the form of lysophosphatidylcholine (LPC), but not unesterified fatty acid, in a sodium-dependent manner.”
Quoted verbatim from Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid..
Study

in vitro · not in humans
Population

cultured cells (cell type not stated in abstract)
Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid.2014PMID:24828044Permalink

Show the remaining 3

Inhibits FBXW7
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Hypothesis
“Mechanistically, DHA inhibited the ubiquitination of NRF1 via the cytoplasmic E3 ligases FBW7 and HRD1 at the ER membrane, thereby preventing its degradation.”
Quoted verbatim from NRF1 is upregulated by docosahexaenoic acid to ameliorate MASH through the inhibition of ER stress..
Study

mechanistic · not in humans
Population

not stated in the abstract
NRF1 is upregulated by docosahexaenoic acid to ameliorate MASH through the inhibition of ER stress.2026PMID:41545342Permalink
Inhibits SYVN1
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Hypothesis
“Mechanistically, DHA inhibited the ubiquitination of NRF1 via the cytoplasmic E3 ligases FBW7 and HRD1 at the ER membrane, thereby preventing its degradation.”
Quoted verbatim from NRF1 is upregulated by docosahexaenoic acid to ameliorate MASH through the inhibition of ER stress..
Study

mechanistic · not in humans
Population

not stated in the abstract
NRF1 is upregulated by docosahexaenoic acid to ameliorate MASH through the inhibition of ER stress.2026PMID:41545342Permalink
Binds PPARD
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Hypothesis
“Molecular docking, molecular dynamics simulations, and mutagenesis experiments suggest that DHA binds to PPARD in a distinct manner compared to OA, which may help explain their differing abilities to influence the expression of heart regeneration genes.”
Quoted verbatim from Accumulation of newly synthesized docosahexaenoic acid plays an essential role in heart regeneration..
Study

mechanistic · not in humans
Population

computational molecular docking, molecular dynamics simulation, and mutagenesis experiments
Accumulation of newly synthesized docosahexaenoic acid plays an essential role in heart regeneration.2026PMID:40851370Permalink

What did not

1 finding

No detected effect on adverse event occurrence (oral or enteral supplement)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“Overall, there were no significant differences in the incidence, type, or severity of adverse effects reported in the placebo or DHA group.”
Quoted verbatim from Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial..
Study

RCT
Duration

4 months
Dose

4.4 g/day DHA-enriched algae triacylglycerol (11 x 400 mg capsules/day), oral, concurrent with 6 cycles (18 weeks) of neoadjuvant chemotherapy
Population

women with stage I-III non-metastatic breast cancer undergoing neoadjuvant chemotherapy
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.2025PMID:40490846Industry fundedPermalink

What it touches on the way

Mechanistic reach

40 entities

40 entities reached.

0 reported hops40 assembled from the scaffold

Show the remaining 28

What the reference databases state

Chemical structure

1-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-N-(acetyl)-sphing-4-enine has the functional parent all-cis-docosa-4,7,10,13,16,19-hexaenoic acidCompoundChEBI CHEBI:76087Inferred only
1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine has the functional parent all-cis-docosa-4,7,10,13,16,19-hexaenoic acidCompoundChEBI CHEBI:74963Inferred only
1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycerol has the functional parent all-cis-docosa-4,7,10,13,16,19-hexaenoic acidCompoundChEBI CHEBI:82949Inferred only
1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine has the functional parent all-cis-docosa-4,7,10,13,16,19-hexaenoic acidCompoundChEBI CHEBI:84829Inferred only
1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycerol has the functional parent all-cis-docosa-4,7,10,13,16,19-hexaenoic acidCompoundChEBI CHEBI:77129Inferred only
1-tetradecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine has the functional parent all-cis-docosa-4,7,10,13,16,19-hexaenoic acidCompoundChEBI CHEBI:86162Inferred only
2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine has the functional parent all-cis-docosa-4,7,10,13,16,19-hexaenoic acidCompoundChEBI CHEBI:76085Inferred only
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl ethanolamine has the functional parent all-cis-docosa-4,7,10,13,16,19-hexaenoic acidCompoundChEBI CHEBI:85252Inferred only

Statements

89 statements

89 statements · 2 reference databases · Subject: all-cis-docosa-4,7,10,13,16,19-hexaenoic acid · Sources: Human-GEM, Rhea

Order

all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is converted to (11S)-hydroperoxy-(4Z,7Z,9E,13Z,16Z,19Z)-docosahexaenoateCompoundRhea RHEA:64732Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is converted to (14S)-hydroperoxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoateCompoundRhea RHEA:41332Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is converted to (17S)-hydroperoxy-(4Z,7Z,10Z,13Z,15E,19Z)-docosahexaenoateCompoundRhea RHEA:50840Inferred only
(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-CoA is converted to all-cis-docosa-4,7,10,13,16,19-hexaenoic acidCompoundRhea RHEA:67700Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is converted to (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-CoACompoundRhea RHEA:44932Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is converted to (7S)-hydroperoxy-(4Z,8E,10Z,13Z,16Z,19Z)-docosahexaenoateCompoundRhea RHEA:64668Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is converted to 14-hydroperoxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoateCompoundRhea RHEA:43472Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is converted to 21-hydroxy-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoateCompoundHuman-GEM MAR20025Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is converted to 21-hydroxy-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoateCompoundHuman-GEM MAR20026Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP1A1ProteinRhea RHEA:52120Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP1A1ProteinRhea RHEA:52124Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP1A2ProteinRhea RHEA:52120Inferred only

Show the remaining 77

all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2C19ProteinRhea RHEA:50088Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2C19ProteinRhea RHEA:52120Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2C19ProteinRhea RHEA:52124Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2C8ProteinRhea RHEA:52120Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2C8ProteinRhea RHEA:52124Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2D6ProteinRhea RHEA:52124Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2D6ProteinRhea RHEA:52120Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2E1ProteinHuman-GEM MAR20025Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2E1ProteinHuman-GEM MAR20026Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2E1ProteinRhea RHEA:50088Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2J2ProteinRhea RHEA:52120Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP2J2ProteinRhea RHEA:52124Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP3A4ProteinRhea RHEA:52120Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP3A4ProteinRhea RHEA:52124Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F11ProteinRhea RHEA:40155Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F12ProteinRhea RHEA:51084Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F12ProteinRhea RHEA:51092Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F12ProteinRhea RHEA:51088Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F12ProteinRhea RHEA:51080Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F2ProteinRhea RHEA:40155Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F3ProteinRhea RHEA:50088Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F3ProteinRhea RHEA:40155Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F8ProteinRhea RHEA:51092Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F8ProteinRhea RHEA:51084Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F8ProteinRhea RHEA:51088Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4F8ProteinRhea RHEA:51080Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is metabolised by CYP4V2ProteinRhea RHEA:40155Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSBG1ProteinHuman-GEM MAR02988Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSBG1ProteinHuman-GEM MAR00377Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSBG2ProteinHuman-GEM MAR02988Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSBG2ProteinHuman-GEM MAR00377Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL1ProteinHuman-GEM MAR00377Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL1ProteinHuman-GEM MAR02988Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL3ProteinHuman-GEM MAR02988Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL3ProteinRhea RHEA:44932Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL3ProteinHuman-GEM MAR00377Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL4ProteinHuman-GEM MAR02988Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL4ProteinRhea RHEA:44932Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL4ProteinHuman-GEM MAR00377Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL5ProteinHuman-GEM MAR02988Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL5ProteinHuman-GEM MAR00377Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL6ProteinHuman-GEM MAR00377Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ACSL6ProteinHuman-GEM MAR02988Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ALOX12ProteinRhea RHEA:41332Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ALOX12BProteinRhea RHEA:43472Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ALOX15ProteinRhea RHEA:41332Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ALOX15ProteinRhea RHEA:50840Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ALOX15ProteinRhea RHEA:64732Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ALOX5ProteinRhea RHEA:64668Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ALOX5ProteinRhea RHEA:50840Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of ALOX5ProteinRhea RHEA:41332Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of DAGLBProteinRhea RHEA:63436Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of PTGS2ProteinRhea RHEA:48816Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of PTGS2ProteinRhea RHEA:48820Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of SLC27A2ProteinHuman-GEM MAR02988Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of SLC27A2ProteinHuman-GEM MAR00377Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a substrate of SLC27A2ProteinRhea RHEA:44932Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by ABCA1ProteinHuman-GEM MAR00379Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by ABCD3ProteinRhea RHEA:67704Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by CD36ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by FABP1ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by FABP12ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by FABP2ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by FABP3ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by FABP4ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by FABP5ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by FABP6ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by FABP7ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by FABP9ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by SLC27A1ProteinHuman-GEM MAR08945Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by SLC27A1ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by SLC27A3ProteinHuman-GEM MAR08945Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by SLC27A3ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by SLC27A4ProteinHuman-GEM MAR08945Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by SLC27A4ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by SLC27A6ProteinHuman-GEM MAR00376Inferred only
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid is transported by SLC27A6ProteinHuman-GEM MAR08945Inferred only

Reactions

67 reactions

fatty acid0.0001MAM00003e+0.0001(11Z,14Z)-eicosadienoate+0.0001MAM00010e+0.0001MAM00017e+0.0001MAM00019e+0.0001MAM00021e+0.0001MAM00094e+0.0001MAM00104e+0.0001MAM00111e+0.0001MAM00114e+0.0001MAM00115e+0.0001MAM00117e+0.0001MAM00128e+0.0001MAM00132e+0.0001MAM00135e+0.0001MAM00260e+0.0001MAM00265e+0.0001MAM00315e+0.0001MAM00341e+0.0001MAM01197e+0.0001MAM01207e+0.0001MAM01235e+0.0001MAM01238e+0.0001(7Z,10Z,13Z,16Z)-docosatetraenoate+0.0082(5Z,8Z,11Z,14Z)-eicosatetraenoate+0.0001docosanoate+0.0001hexacosanoate+0.0001MAM01582e+0.0001MAM01583e+0.0001(11Z)-eicosenoate+0.0001MAM01585e+0.0041all-cis-docosa-4,7,10,13,16,19-hexaenoic acid+0.002(8Z,11Z,14Z)-eicosatrienoate+0.0001(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate+0.0001eicosanoate+0.0001elaidic acid+0.001(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate+0.0001MAM01932e+0.0001MAM02053e+0.0001dodecanoate+0.0001tetracosanoate+0.1535linoleic acid+0.0092alpha-linolenic acid+0.0001MAM02456e+0.0001(5Z,8Z,11Z)-eicosatrienoate+0.0338tetradecanoate+0.0001(15Z)-tetracosenoate+0.0001MAM02613e+0.3837(9Z)-octadecenoate+0.0001MAM02648e+0.3015hexadecanoic acid+0.0522(9Z)-hexadecenoate+0.0001MAM02690e+0.0001MAM02745e+0.046octadecanoate+0.0001MAM02939e+0.0001tricosanoate+0.0001MAM03051e+0.0001(17Z)-hexacosenoate
Reaction pageLeft to rightBalance undeterminableextracellular space
Human-GEM MAR00012CC BY 4.0Reference data
MAM02560e0.0048MAM00003e+0.0016(11Z,14Z)-eicosadienoate+0.0016MAM00010e+0.0001MAM00017e+0.0001MAM00019e+0.0001MAM00021e+0.0001MAM00094e+0.0001MAM00104e+0.0001MAM00111e+0.0001MAM00114e+0.0001MAM00115e+0.0001MAM00117e+0.0001MAM00128e+0.0001MAM00132e+0.0001MAM00135e+0.0001MAM00260e+0.0001MAM00265e+0.0001MAM00315e+0.0001MAM00341e+0.0001MAM01197e+0.0001MAM01207e+0.0001MAM01235e+0.0001MAM01238e+0.0017(7Z,10Z,13Z,16Z)-docosatetraenoate+0.0137(5Z,8Z,11Z,14Z)-eicosatetraenoate+0.0007docosanoate+0.0005hexacosanoate+0.0001MAM01582e+0.0002MAM01583e+0.0001(11Z)-eicosenoate+0.0001MAM01585e+0.0046all-cis-docosa-4,7,10,13,16,19-hexaenoic acid+0.0025(8Z,11Z,14Z)-eicosatrienoate+0.0019(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate+0.0011eicosanoate+0.0001elaidic acid+0.002(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate+0.0048MAM01932e+0.0001MAM02053e+0.0034dodecanoate+0.0012tetracosanoate+0.071linoleic acid+0.0005alpha-linolenic acid+0.0056MAM02456e+0.0005(5Z,8Z,11Z)-eicosatrienoate+0.0283tetradecanoate+0.0003(15Z)-tetracosenoate+0.0001MAM02613e+0.3746(9Z)-octadecenoate+0.0001MAM02648e+0.2949hexadecanoic acid+0.0686(9Z)-hexadecenoate+0.003MAM02690e+0.0001MAM02745e+0.1031octadecanoate+0.0001MAM02939e+0.0002tricosanoate+0.0001MAM03051e+0.0001(17Z)-hexacosenoate
Reaction pageLeft to rightBalance undeterminableextracellular space
Human-GEM MAR00015CC BY 4.0Reference data
0.0001MAM00003e+0.0023(11Z,14Z)-eicosadienoate+0.0003MAM00010e+0.0002MAM00017e+0.003MAM00019e+0.0001MAM00021e+0.0001MAM00094e+0.0001MAM00104e+0.0001MAM00111e+0.0001MAM00114e+0.0001MAM00115e+0.0004MAM00117e+0.0023MAM00128e+0.0001MAM00132e+0.0001MAM00135e+0.0001MAM00260e+0.0001MAM00265e+0.0001MAM00315e+0.0001MAM00341e+0.0045MAM01197e+0.0002MAM01207e+0.001MAM01235e+0.0037MAM01238e+0.0008(7Z,10Z,13Z,16Z)-docosatetraenoate+0.0051(5Z,8Z,11Z,14Z)-eicosatetraenoate+0.0002docosanoate+0.0001hexacosanoate+0.0001MAM01582e+0.0002MAM01583e+0.0046(11Z)-eicosenoate+0.0204MAM01585e+0.0012all-cis-docosa-4,7,10,13,16,19-hexaenoic acid+0.0021(8Z,11Z,14Z)-eicosatrienoate+0.0009(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate+0.0009eicosanoate+0.0001elaidic acid+0.0009(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate+0.0005MAM01932e+0.0001MAM02053e+0.0061dodecanoate+0.0001tetracosanoate+0.1573linoleic acid+0.0073alpha-linolenic acid+0.0001MAM02456e+0.0001(5Z,8Z,11Z)-eicosatrienoate+0.035tetradecanoate+0.0001(15Z)-tetracosenoate+0.0001MAM02613e+0.383(9Z)-octadecenoate+0.0004MAM02648e+0.2478hexadecanoic acid+0.0395(9Z)-hexadecenoate+0.0039MAM02690e+0.0001MAM02745e+0.0613octadecanoate+0.0001MAM02939e+0.0001tricosanoate+0.0001MAM03051e+0.0001(17Z)-hexacosenoateMAM02561e
Reaction pageLeft to rightBalance undeterminableextracellular space
Human-GEM MAR00016CC BY 4.0Reference data
all-cis-docosa-4,7,10,13,16,19-hexaenoic acidall-cis-docosa-4,7,10,13,16,19-hexaenoic acid
Transported by SLC27A6 or FABP3 or SLC27A1 or CD36 or SLC27A3 or FABP2 or FABP1 or FABP7 or FABP5 or SLC27A4 or FABP6 or FABP4 and 2 more alternatives
Reaction pageLeft to rightBalancedextracellular space, cytosol
Human-GEM MAR00376CC BY 4.0Reference data
ATP+CHEBI:1146900+all-cis-docosa-4,7,10,13,16,19-hexaenoic acid(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-CoA+AMP+diphosphate(3-)
Catalysed by ACSL4 or ACSBG1 or ACSL3 or ACSBG2 or SLC27A2 or ACSL1 or ACSL6 or ACSL5
Reaction pageLeft to rightBalancedEC 6.2.1.3cytosol
Human-GEM MAR00377CC BY 4.0Reference data
(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-CoA+waterCHEBI:1146900+all-cis-docosa-4,7,10,13,16,19-hexaenoic acid+proton
Catalysed by BAAT or ACOT6
Reaction pageLeft to rightBalancedEC 3.1.2.2cytosol
Human-GEM MAR00378CC BY 4.0Reference data
ATP+all-cis-docosa-4,7,10,13,16,19-hexaenoic acid+waterADP+all-cis-docosa-4,7,10,13,16,19-hexaenoic acid+proton+phosphate(3-)
Transported by ABCA1
Reaction pageLeft to rightBalancedcytosol, extracellular space
Human-GEM MAR00379CC BY 4.0Reference data
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid
Reaction pageReversibleBalance undeterminableextracellular space
Human-GEM MAR00573CC BY 4.0Reference data
fatty acid0.0001MAM00003c+0.0001(11Z,14Z)-eicosadienoate+0.0001MAM00010c+0.0001MAM00017c+0.0001MAM00019c+0.0001MAM00021c+0.0001MAM00094c+0.0001MAM00104c+0.0001MAM00111c+0.0001MAM00114c+0.0001MAM00115c+0.0001MAM00117c+0.0001MAM00128c+0.0001MAM00132c+0.0001MAM00135c+0.0001MAM00260c+0.0001MAM00265c+0.0001MAM00315c+0.0001MAM00341c+0.0001MAM01197c+0.0001MAM01207c+0.0001MAM01235c+0.0001MAM01238c+0.0001(7Z,10Z,13Z,16Z)-docosatetraenoate+0.0024(5Z,8Z,11Z,14Z)-eicosatetraenoate+0.0001docosanoate+0.0001hexacosanoate+0.0001MAM01582c+0.0001MAM01583c+0.0001(11Z)-eicosenoate+0.0208MAM01585c+0.0005all-cis-docosa-4,7,10,13,16,19-hexaenoic acid+0.0013(8Z,11Z,14Z)-eicosatrienoate+0.0017(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate+0.0001eicosanoate+0.0001elaidic acid+0.0013(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate+0.0048MAM01932c+0.0001MAM02053c+0.0001dodecanoate+0.0001tetracosanoate+0.0741linoleic acid+0.0037alpha-linolenic acid+0.0001MAM02456c+0.0001(5Z,8Z,11Z)-eicosatrienoate+0.0096tetradecanoate+0.0001(15Z)-tetracosenoate+0.0001MAM02613c+0.122(9Z)-octadecenoate+0.0001MAM02648c+0.64hexadecanoic acid+0.0286(9Z)-hexadecenoate+0.0001MAM02690c+0.0001MAM02745c+0.082octadecanoate+0.0028MAM02939c+0.0001tricosanoate+0.0001MAM03051c+0.0001(17Z)-hexacosenoate
Reaction pageLeft to rightBalance undeterminablecytosol
Human-GEM MAR00685CC BY 4.0Reference data
fatty acid0.0001MAM00003c+0.0001(11Z,14Z)-eicosadienoate+0.0001MAM00010c+0.0001MAM00017c+0.0001MAM00019c+0.0001MAM00021c+0.0016MAM00094c+0.0001MAM00104c+0.0001MAM00111c+0.0001MAM00114c+0.0001MAM00115c+0.0001MAM00117c+0.0001MAM00128c+0.0001MAM00132c+0.0001MAM00135c+0.0001MAM00260c+0.0001MAM00265c+0.0001MAM00315c+0.0001MAM00341c+0.0001MAM01197c+0.0001MAM01207c+0.0001MAM01235c+0.0001MAM01238c+0.0032(7Z,10Z,13Z,16Z)-docosatetraenoate+0.0521(5Z,8Z,11Z,14Z)-eicosatetraenoate+0.0001docosanoate+0.0001hexacosanoate+0.0001MAM01582c+0.0001MAM01583c+0.0001(11Z)-eicosenoate+0.0217MAM01585c+0.0081all-cis-docosa-4,7,10,13,16,19-hexaenoic acid+0.0023(8Z,11Z,14Z)-eicosatrienoate+0.0018(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate+0.0001eicosanoate+0.0001elaidic acid+0.0003(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate+0.003MAM01932c+0.0001MAM02053c+0.0001dodecanoate+0.0001tetracosanoate+0.281linoleic acid+0.0119alpha-linolenic acid+0.0001MAM02456c+0.0001(5Z,8Z,11Z)-eicosatrienoate+0.0024tetradecanoate+0.0001(15Z)-tetracosenoate+0.0001MAM02613c+0.4226(9Z)-octadecenoate+0.0001MAM02648c+0.12hexadecanoic acid+0.0229(9Z)-hexadecenoate+0.0001MAM02690c+0.0001MAM02745c+0.0384octadecanoate+0.0025MAM02939c+0.0001tricosanoate+0.0001MAM03051c+0.0001(17Z)-hexacosenoate
Reaction pageLeft to rightBalance undeterminablecytosol
Human-GEM MAR00686CC BY 4.0Reference data
fatty acid0.0001MAM00003c+0.0001(11Z,14Z)-eicosadienoate+0.0001MAM00010c+0.0001MAM00017c+0.0001MAM00019c+0.0001MAM00021c+0.0011MAM00094c+0.0001MAM00104c+0.0001MAM00111c+0.0001MAM00114c+0.0001MAM00115c+0.0001MAM00117c+0.0001MAM00128c+0.0001MAM00132c+0.0001MAM00135c+0.0001MAM00260c+0.0001MAM00265c+0.0001MAM00315c+0.0001MAM00341c+0.0001MAM01197c+0.0001MAM01207c+0.0001MAM01235c+0.0001MAM01238c+0.0022(7Z,10Z,13Z,16Z)-docosatetraenoate+0.0264(5Z,8Z,11Z,14Z)-eicosatetraenoate+0.0001docosanoate+0.0001hexacosanoate+0.0001MAM01582c+0.0001MAM01583c+0.0001(11Z)-eicosenoate+0.0194MAM01585c+0.0221all-cis-docosa-4,7,10,13,16,19-hexaenoic acid+0.0141(8Z,11Z,14Z)-eicosatrienoate+0.0038(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate+0.0001eicosanoate+0.0001elaidic acid+0.0035(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate+0.0081MAM01932c+0.0001MAM02053c+0.0001dodecanoate+0.0001tetracosanoate+0.278linoleic acid+0.0023alpha-linolenic acid+0.0001MAM02456c+0.0001(5Z,8Z,11Z)-eicosatrienoate+0.003tetradecanoate+0.0001(15Z)-tetracosenoate+0.0001MAM02613c+0.4519(9Z)-octadecenoate+0.0001MAM02648c+0.0849hexadecanoic acid+0.014(9Z)-hexadecenoate+0.0001MAM02690c+0.0001MAM02745c+0.0584octadecanoate+0.0026MAM02939c+0.0001tricosanoate+0.0001MAM03051c+0.0001(17Z)-hexacosenoate
Reaction pageLeft to rightBalance undeterminablecytosol
Human-GEM MAR00687CC BY 4.0Reference data
fatty acid0.0005MAM00003c+0.0005(11Z,14Z)-eicosadienoate+0.0005MAM00010c+0.0005MAM00017c+0.0005MAM00019c+0.0005MAM00021c+0.0039MAM00094c+0.0005MAM00104c+0.0005MAM00111c+0.0005MAM00114c+0.0005MAM00115c+0.0005MAM00117c+0.0005MAM00128c+0.0005MAM00132c+0.0005MAM00135c+0.0005MAM00260c+0.0005MAM00265c+0.0005MAM00315c+0.0005MAM00341c+0.0005MAM01197c+0.0005MAM01207c+0.0005MAM01235c+0.0005MAM01238c+0.0011(7Z,10Z,13Z,16Z)-docosatetraenoate+0.0709(5Z,8Z,11Z,14Z)-eicosatetraenoate+0.0005docosanoate+0.0005hexacosanoate+0.0005MAM01582c+0.0005MAM01583c+0.0005(11Z)-eicosenoate+0.0271MAM01585c+0.0252all-cis-docosa-4,7,10,13,16,19-hexaenoic acid+0.0228(8Z,11Z,14Z)-eicosatrienoate+0.0056(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate+0.0005eicosanoate+0.0005elaidic acid+0.0109(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate+0.0036MAM01932c+0.0005MAM02053c+0.0005dodecanoate+0.0005tetracosanoate+0.2479linoleic acid+0.0047alpha-linolenic acid+0.0005MAM02456c+0.0005(5Z,8Z,11Z)-eicosatrienoate+0.0054tetradecanoate+0.0005(15Z)-tetracosenoate+0.0005MAM02613c+0.1143(9Z)-octadecenoate+0.0178MAM02648c+0.2781hexadecanoic acid+0.0105(9Z)-hexadecenoate+0.0005MAM02690c+0.0005MAM02745c+0.1271octadecanoate+0.0026MAM02939c+0.0005tricosanoate+0.0005MAM03051c+0.0005(17Z)-hexacosenoate
Reaction pageReversibleBalance undeterminablecytosol
Human-GEM MAR00688CC BY 4.0Reference data

Show the remaining 55

On the label

Labelled products

628 products

Source: NIH DSLD · Ingredient: all-cis-docosa-4,7,10,13,16,19-hexaenoic acid · 628 products · Declared amount per serving: 0.5–3,380 mg (613 products)

623 labels state an amount5 do not

Order

1MDKrillMD120 mgper 2 Softgel(s)DSLD:246767
1st PhormMicro Factor EFAFish Oil100 mgper 1 Softgel(s)DSLD:295905
21st CenturyDHASchizochytrium sp. Oil200 mgper 1 Softgel(s)DSLD:258550
21st CenturyDHASchizochytrium sp. Oil200 mgper 1 Softgel(s)DSLD:282959
21st CenturyDHA 200 Plant-Sourced Omega-3Algal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Softgel(s)DSLD:11404
21st CenturyDHA 300 High Potency Plant-Sourced Omega-3Algal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)300 mgper 1 Softgel(s)DSLD:11409
21st CenturyOcuHealth Full Spectrum Formula High Potency AntioxidantMarine Algae · DHA (Form: fron Marine Algae) (Alt. Name: Docosahexaenoic Acid)20 mgper 2 Tablet(s)DSLD:11491
21st Century VitaJoy GummiesOmega + DHAAlgae · DHA (Form: from Algae)50 mgper 3 Gummy(ies)DSLD:207612
21st Century Zoo FriendsSmart Kids Omega plus DHAAlgae · DHA (Form: from Algae)16.7 mgper 1 Gummy(ies)DSLD:207608
8WeeksOutIntellect100 mgper 3 Capsule(s)DSLD:228495
AB American BiologicsImproved Super Omega EPA/DHADHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3240 mgper 2 Softgel(s)DSLD:20294
AB American BiologicsUltra Omega EssentialsDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3110 mgper 2 Softgel(s)DSLD:20491

Show the remaining 616

AbbottDHA/Lutein/Vitamin E SoftgelFish Oil Concentrate · DHA (Form: from Fish Oil concentrate (Form: Anchovy, Sardine, Jack Mackerel, Tuna)) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Softgel(s)DSLD:69993
AbbottDHA/Lutein/Vitamin E SoftgelFish Oil Concentrate · DHA (Form: from Fish Oil concentrate (Form: Anchovy, Sardine, Jack Mackerel, Tuna)) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Softgel(s)DSLD:69999
Abbott NutritionSimilac Breastfeeding SupplementFish Oil Concentrate200 mgper 1 Softgel(s)DSLD:270268
Absorb HealthOmega DHA & EPADHA (Alt. Name: Docosahexaenoic Acid) Note: Gas Chromatography by A%.480 mgper 2 Softgel(s)DSLD:216055
Acella PharmaceuticalsPNV DHADocosahexaenoic Acid (Form: from Omega-3 Fatty Acids) (Alt. Name: DHA)300 mgper 1 Softgel(s)DSLD:239560
Acella PharmaceuticalsPNV-DHADocosahexaenoic Acid (Form: from Omega-3 Fatty Acids) (Alt. Name: DHA)300 mgper 1 Tablet(s)DSLD:45702
Acella PharmaceuticalsPNV-Omega300 mgper 1 Softgel(s)DSLD:278709
Advanced Nutrition by ZahlerMighty MiniAlgal Oil100 mgper 1 Softgel(s)DSLD:260232
AdvoCareCore Nutrition SystemMarine Lipids · Docosahexaenoic Acid (Form: from Marine Lipids)400 mgper 1 4-Packet Strip(s)DSLD:177397
AdvoCareMNS 3Marine Lipids · Docosahexaenoic Acid (Form: from Marine Lipids)400 mgper 2 Packet(s)DSLD:177961
AdvoCareMNS CMarine Lipids · Docosahexaenoic Acid (Form: from Marine Lipids)200 mgper 2 Packet(s)DSLD:207148
AdvoCareMNS EMarine Lipids · Docosahexaenoic Acid (Form: from Marine Lipids)200 mgper 1 Packet(s)DSLD:177964
AdvoCareOmegaPlexMarine Lipids400 mgper 2 Softgel(s)DSLD:265350
AdvoCarePurple Champs Acai Berry80 mgper 2 Chew(s)DSLD:178345
Alani NuPrenatal200 mgper 2 Softgel(s)DSLD:277637
Allergy Research GroupSteady On110 mgper 20 Gram(s)DSLD:54474
Allergy Research GroupSteady On110 mgper 20 Gram(s)DSLD:54482
Allergy Research GroupTake Heart II Without Hormones95 mgper 20 Gram(s)DSLD:54484
Allergy Research GroupTake Heart II Without Hormones95 mgper 20 Gram(s)DSLD:54477
Amala VeganKids Vegan Omega 3 DHA + EPA Organic Lemon Flavored250 mgper 0.5 mLDSLD:276164
AmerifitDHA SoftgelAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)350 mgper 1 Softgel(s)DSLD:29021
AmeriFitBrainStrong KidsAlgal Oil · DHA Note: docosahexaenoic acid from algal oil100 mgper 1 Gummy(ies)DSLD:2494
AmeriFitBrainStrong ToddlerAlgal Oil · DHA Note: docosahexaenoic acid from algal oil100 mgper 1 Packet(s)DSLD:2495
AmvilabOmega 3-6-9Fish Oil100 mgper 1 Softgel(s)DSLD:298165
AN Amazing Nutrition Amazing OmegaFish Oil 1000 mg22%120 mgper 1 Softgel(s)DSLD:275821
AN Amazing Nutrition Amazing OmegaKrill Oil 500 mg32 mgper 1 Softgel(s)DSLD:251769
ANTIAGING Institute of CaliforniaFish Oil Concentrate120 mgper 1 Softgel(s)DSLD:210294
AOR Advanced Orthomolecular Research PremiumVegan Omega 3Typical values. Ranges: DHA 300-400 mg316 mgper 1 Softgel(s)DSLD:305920
Apex EnergeticsOmegaCo3 (K-7)350 mgper 1 TbspDSLD:206624
Apex EnergeticsOmegaCo3-SE375 mgper 2 Softgel(s)DSLD:239380
AquaOmegaHigh DHA Omega-3 4500 mg Lemon Flavor3,380 mgper 7.5 mLDSLD:277089
AquaOmegaHigh EPA Omega-3 Lemon Flavor670 mgper 7.5 mLDSLD:275942
AquaOmegaHigh EPA Omega-3 Orange Flavor670 mgper 7.5 mLDSLD:275944
aSquared NutritionOmega 3 2400 mg Lemon Flavored430 mgper 2 Softgel(s)DSLD:322074
Avion PharmaceuticalsPrenate DHAFish Oil · Docosahexaenoic Acid (Form: from Omega-3 Fatty Acids (Form: from Fish Oil)) (Alt. Name: DHA)300 mgper 1 Softgel(s)DSLD:25833
Avion PharmaceuticalsPrenate DHA300 mgper 1 Softgel(s)DSLD:279278
Avion PharmaceuticalsPrenate DHA300 mgper 1 Softgel(s)DSLD:44767
Avion PharmaceuticalsPrenate Enhance400 mgper 1 Softgel(s)DSLD:279277
Avion PharmaceuticalsPrenate Enhance400 mgper 1 Softgel(s)DSLD:44772
Avion PharmaceuticalsPrenate Essential300 mgper 1 Softgel(s)DSLD:279279
Avion PharmaceuticalsPrenate Essential300 mgper 1 Softgel(s)DSLD:44774
Avion PharmaceuticalsPrenate Mini350 mgper 1 Softgel(s)DSLD:44778
Avion PharmaceuticalsPrenate Pixie200 mgper 1 Soft Gel(s)DSLD:279281
Avion PharmaceuticalsPrenate Pixie200 mgper 1 Softgel(s)DSLD:44781
Avion PharmaceuticalsPrenate Restore400 mgper 1 Softgel(s)DSLD:278690
Avion PharmaceuticalsPrenate Restore400 mgper 1 Softgel(s)DSLD:44997
Avion PharmaceuticalsPrimaCare300 mgper 1 Softgel(s)DSLD:278712
Barlean'sTotal Omega 3-6-9 Lemonade Flavor200 mgper 3 Gram(s)DSLD:218507
Barlean's Organic OilsIdeal Omega 3 Orange Flavored250 mgper 1 Softgel(s)DSLD:220029
Basic VitaminsOderless Coated Fish Oil 1000 mg Omega-3120 mgper 1 Softgel(s)DSLD:250298
BayerArctic Wonder Omega-3 Krill Oil90 mgper 2 Softgel(s)DSLD:12238
BayerFlintstones Gummies Complete plus Omega-3 DHAAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)32 mgper 1 Gummy(ies)DSLD:45138
BayerFlintstones SupplementsAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Gummy(ies)DSLD:70315
Bayer One A DayVitaCraves Gummies +Omega-3 DHA Fruit Punch FlavoredAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)32 mgper 2 Gummy(ies)DSLD:17180
Bayer One A DayWomen's Prenatal Gummies50 mgper 2 Gummy(ies)DSLD:270736
Bayer One A DayWomen's Prenatal Gummies with Folic Acid50 mgper 2 Gummie(s)DSLD:269824
Bayer One A Day AdultVitaCraves Multi + Omega-3 DHA Gummies Fruit Punch FlavorAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)32 mgper 2 Gummie(s)DSLD:178148
Best NaturalsKrill-500 1000 mgTypical fatty Acid104 mgper 1 Softgel(s)DSLD:270590
Best NaturalsKrill-500 500 mgTypical fatty Acid104 mgper 2 Softgel(s)DSLD:270589
Best Nest WellnessOne Fish, Two Fish500 mgper 2 Softgel(s)DSLD:270752
Beyond HealthFish Oil Formula500 mgper 2 Softgel(s)DSLD:306889
Beyond HumanOmega 3 Fish Oil120 mgper 1 Soft Gelatin Capsule(s)DSLD:181952
Bio NutritionBrain WellnessDHA Note: Source: Veg50 mgper 2 Vegetable Capsule(s)DSLD:200631
Bio NutritionK Bio Krill 500 mg52 mgper 1 Softgel(s)DSLD:200593
BioChem SportsOmega BurnMarine Lipids · Docosahexaenoic acid (Form: from marine lipid (Form: Anchovy, Sardine, Mackerel, algae (Form: Chrysophyceae))) (Alt. Name: DHA)233 mgper 6 Softgel(s)DSLD:13312
BIOVEADHA 100 mgFish Oil · Docosahexaenoic Acid (Form: from Fish Oil) (Alt. Name: DHA)100 mgper 1 Softgel(s)DSLD:249071
BIOVEAPrenatal Multi with DHAFish Oil · DHA (Form: from Fish Oil)25 mgper 3 Tablet(s)DSLD:45457
BluebonnetLadies One Prenatal DHAAlgal Oil200 mgper 1 Vegetarian Softgel(s)DSLD:332515
BluebonnetLadies One Prenatal DHA 200 mgAlgal Oil200 mgper 1 Vegetarian Softgel(s)DSLD:332514
BluebonnetNatural Omega-3 Vegetarian DHA 100 mgAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Vegetarian Capsule(s)DSLD:178926
BluebonnetNatural Omega-3 Vegetarian DHA 100 mgAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Vegetarian Softgel(s)DSLD:178936
BluebonnetNatural Omega-3 Vegetarian DHA 200 mgAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Vegetarian Softgel(s)DSLD:178937
BluebonnetOmega-3 Vegetarian DHA 200 mgAlgal Oil200 mgper 1 Vegetarian Softgel(s)DSLD:280178
BluebonnetOmega-3 Vegetarian DHA 200 mgAlgal Oil200 mgper 1 Vegetarian Softgel(s)DSLD:316455
Bluebonnet Early Promise PrenatalGentle DHA 100 mgAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Vegetarian Softgel(s)DSLD:176715
Bluebonnet Early Promise PrenatalGentle DHA 100 mgAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Vegetarian Softgel(s)DSLD:176718
Bluebonnet Early Promise PrenatalGentle DHA 200 mgAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Vegetarian Softgel(s)DSLD:176709
Bluebonnet Early Promise PrenatalGentle DHA 200 mgAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Vegetarian Softgel(s)DSLD:176785
Bluebonnet Early Promise PrenatalGentle DHA 200 mgAlgal Oil200 mgper 1 Vegetarian Softgel(s)DSLD:280070
Bluebonnet Early Promise PrenatalGentle DHA 200 mgAlgal Oil200 mgper 1 Vegetarian Softgel(s)DSLD:280071
Bluebonnet Intimate EssentialsFor Her Fertility SupportAlgal Oil50 mgper 1 Capsule(s)DSLD:315069
Bluebonnet Targeted ChoiceEyeCare25 mgper 2 Capsule(s)DSLD:314968
Bluebonnet Targeted ChoiceEyeCare25 mgper 2 Capsule(s)DSLD:316445
BocaGreenMDDHAAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)300 mgper 1 Softgel(s)DSLD:43221
BocaGreenMDPrena1 With QuatrefolicAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Softgel(s)DSLD:43222
BonGeo PharmaceuticalsTendera-OB Prenatal Multivitamin + DHAFish Oil · Omega-3 Fish Oil205 mgper 1 Softgel(s)DSLD:263450
BrainStrongAdultAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)900 mgper 3 Softgel(s)DSLD:60817
BrainStrongAdultAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)900 mgper 3 Softgel(s)DSLD:60818
Bright BrainChill + Relaxomega 350 mgper 1 Capsule(s)DSLD:318241
BronsonLife's DHA 200 mgDocosahexaenoic Acid Ethyl Ester · As ethyl esters200 mgper 1 Softgel(s)DSLD:317329
Bronson LaboratoriesDHA 100 mg100 mgper 1 Softgel(s)DSLD:45725
Bronson LaboratoriesKrill Oil 500 mg90 mgper 2 Softgel(s)DSLD:8247
Bronson LaboratoriesOCU-V+18.75 mgper 1 Capsule(s)DSLD:25432
Bronson LaboratoriesPre & Post-Natal DHA 200 mg200 mgper 1 Softgel(s)DSLD:45484
BulkSupplements.comMultivitamins 1000 mg Softgels100 mgper 1 Softgel(s)DSLD:312978
BulkSupplements.comMultivitamins for Men - with Fish Oil Softgels100 mgper 1 Softgel(s)DSLD:312979
BulkSupplements.comMultivitamins for Men - with Fish Oil Softgels100 mgper 1 Softgel(s)DSLD:314919
BulkSupplements.comMultivitamins for Men - with Fish Oil Softgels 1000 mg100 mcgper 1 Softgel(s)DSLD:329942
BulkSupplements.comMultivitamins for Women - with Fish Oil Softgels100 mgper 1 Softgel(s)DSLD:312980
BulkSupplements.comMultivitamins For Women - with Fish Oil Softgels 1000 mg100 mgper 1 Softgel(s)DSLD:313514
BulkSupplements.comMultivitamins Softgels100 mgper 1 Softgel(s)DSLD:294795
BulkSupplements.comMultivitamins Softgels100 mgper 1 Softgel(s)DSLD:294796
BulkSupplements.comMultivitamins with Fish Oil Softgels 1000 mg100 mgper 1 Softgel(s)DSLD:329778
Buried Treasure Liquid NutrientsJoint Ease + Plus Pomegranate/Raspberry Flavor100 mgper 30 mLDSLD:250686
Burton NutritionUltimate Men's Daily PackFish Oil100 mgper 1 Packet(s)DSLD:306046
California Academy of HealthPure Premium Antarctic Krill Oil 500 mg75 mgper 2 Softgel(s)DSLD:206422
California Gold NutritionDHA 700 Pharmaceutical Grade Fish Oil 1000 mgDHA as TG700 mgper 1 Softgel(s)DSLD:299610
Cardiovascular ResearchNeuromins DHA100 mgper 1 Softgel(s)DSLD:22958
Cardiovascular ResearchNeuromins DHA 100 mg100 mgper 1 Softgel(s)DSLD:304414
CarlsonAble EyesFish Oil · DHA (Form: from Fish Oil, reported as Triglycerides) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Softgel(s)DSLD:209266
CarlsonAble EyesFish Oil · DHA (Form: from Fish Oil, reported as Triglycerides) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Softgel(s)DSLD:209269
CarlsonAble EyesFish Oil · DHA (Form: from Fish Oil, reported as Triglycerides) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Softgel(s)DSLD:216293
CarlsonAble EyesFish Oil · DHA (Form: from Fish Oil, reported as Triglycerides) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Softgel(s)DSLD:216295
CarlsonKid's Norwegian Cod Liver Oil Natural Lemon Flavorreported as triglycerides250 mgper 2.5 mLDSLD:337525
CarlsonOlive Your Heart Basil FlavorDHA (Form: reported as Triglycerides) (Alt. Name: Docosahexaenoic Acid)900 mgper 15 mLDSLD:216674
CarWin Pharmaceutical AssociatesTriStart DHA200 mgper 1 Softgel(s)DSLD:279283
CATALOBaby's Algea Omega-3 Drops432 mgper 0.5 mLDSLD:320578
CATALOBaby's Vegetarian DHA FormulaDocosahexaenoic Acid · Natural Vegetarian3,000 mgper 500 mgDSLD:303015
CATALOChildren's DHA Formulaamount not statedper 1 Chewable Softgel(s)DSLD:303027
CATALOChildren's Vegetarian DHA FormulaDocosahexaenoic Acid · Natural Vegetarian3,000 mgper 500 mgDSLD:303035
CentrumCentrum Specialist Prenatal200 mgper 1 Tablet(s)DSLD:19028
ChildLife EssentialsAlgae DHA Natural Berry FlavorAlgae100 mgper 1 Softgel(s)DSLD:327003
ChildLife EssentialsOmega-3 DHA + Choline SoftChew Gummies Natural Passion Fruit Flavor250 mgper 1 Tablet(s)DSLD:327007
ChildLife EssentialsPure Arctic Cod Liver Oil Natural Strawberry Flavor1,100 mgper 2.5 mLDSLD:241499
Cognetix LabsProvasil5 mgper 1 Tablet(s)DSLD:239432
Cognetix LabsProvasilFish Oil5 mgper 1 Tablet(s)DSLD:274326
CoromegaDHA Algal Oil Orange FlavorAlgal Oil500 mgper 2.5 Gram(s)DSLD:296863
Corr-Jensen LabsAb CutsDHA Oil 70%70 mgper 2 Softgel(s)DSLD:2292
Country LifeBaby Care Prenatal Omega 3-6-9Fish Oil Concentrate · DHA (Form: from Fish Oil concentrate) (Alt. Name: Docosahexaenoic Acid) Note: Omega 3400 mgper 2 Softgel(s)DSLD:182476
Country LifeOmega 3 MoodFish Oil Concentrate · Docosahexaenoic Acid Note: from fish oil concentrate - sardine, anchovy150 mgper 2 Softgel(s)DSLD:1609
Covalent MedicalFocus Support1.5 mgper 1 Tablet(s)DSLD:52852
Covalent MedicalFocus Support1.5 mgper 1 Tablet(s)DSLD:52872
Culturelle BabyStrong BeginningAlgal Oil70 mgper 0.5 mLDSLD:250619
Custom Health CentersOmega III288 mgper 1 Softgel(s)DSLD:272714
Daily HealthOmega 8060 Natural Lemon Flavored576 mgper 2 Softgel(s)DSLD:248017
Daily HealthOmega 8060 Natural Lemon Flavored576 mgper 2 Softgel(s)DSLD:248082
DCDHA 100 mgFish Oil · DHA (Alt. Name: Docosahexaenoic Acid) Note: from Fish Oil100 mgper 1 Softgel(s)DSLD:244548
DCDHA 100 mgFish Oil100 mgper 1 Softgel(s)DSLD:265703
DCDHA 100 mgFish Oil100 mgper 1 Softgel(s)DSLD:265749
DEVANon-Fish Vegan Omega-3 DHA200 mgper 1 Softgel(s)DSLD:12924
Doctor GilmoreHeart Smart Fish Oil Softgels300 mgper 1 Softgel(s)DSLD:182027
Doctor's BestPhosphatidyl Serine Plus DHAAlgae · DHA (Form: Omega-3 from Algae of Schizochytrium sp.) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Veggie Softgel(s)DSLD:82325
Doctor's BestPrenatal EssentialsAlgal (Schizochytrium sp.) Oil250 mgper 4 Veggie Softgel(s)DSLD:271093
Doctor's BestPurely Prenatal DHA 200 mgVegetable Oil · DHA (Form: as Vegetable Oil (Form: from Algae (Form: of Schizochytrium sp. Genus: Schizochytrium Species: sp.))) (Alt. Name: Docosahexaenoic Acid) Note: Omega-3400 mgper 2 Veggie Softgel(s)DSLD:82381
Doctor's BestVegan DHA from Algae 200 mgfrom Algae of Schizochytrium sp.200 mgper 1 Veggie Capsule(s)DSLD:302713
dotFITSuper Omega-3240 mgper 1 Softgel(s)DSLD:12984
Douglas LaboratoriesADDtendNeuromins · DHA (Form: as Neuromins) (Alt. Name: Docosahexaenoic acid)84 mgper 6 Capsule(s)DSLD:10334
Douglas LaboratoriesCardiovascular Health Pack200 mgper 1 Packet(s)DSLD:9599
Douglas LaboratoriesDiabet Support Pack340 mgper 1 Packet(s)DSLD:28174
Douglas LaboratoriesDiabet-Support Pack340 mgper 1 Packet(s)DSLD:9619
Douglas LaboratoriesEssential-4 Nutrition Pack340 mgper 1 Packet(s)DSLD:10038
Douglas LaboratoriesLiquid DHA315 mgper 1 mLDSLD:26907
Douglas LaboratoriesMetabolic Management Pack340 mgper 1 Packet(s)DSLD:9593
Douglas LaboratoriesMetabolic Rejuvenation Week 4 Renew170 mgper 1 PackDSLD:261764
Douglas LaboratoriesNeuromins Algae Source DHAOmega-3 Fatty Acids (Form: as Docosahexaenoic Acid (Alt. Name: DHA))100 mgper 1 Softgel(s)DSLD:10976
Douglas LaboratoriesNeuroToneMicroalgae, Powder · Docosahexaenoic Acid (Form: from Microalgae powder) (Alt. Name: DHA)42 mgper 4 Tablet(s)DSLD:261489
Douglas LaboratoriesSenior Men's Pack340 mgper 1 Packet(s)DSLD:9601
Douglas LaboratoriesUltra Cardio Support Pack340 mgper 1 Packet(s)DSLD:10045
Douglas LaboratoriesUltra Cardio Support Pack340 mgper 1 Packet(s)DSLD:27277
Douglas LaboratoriesUltra Preventive V Plus Chel200 mgper 1 Packet(s)DSLD:9714
Douglas LaboratoriesWeek Four: Renew170 mgper 1 Packet(s)DSLD:231039
Douglas LaboratoriesWeek Four: Renew340 mgper 2 Packet(s)DSLD:63562
Douglas LaboratoriesWeek Four: Repair340 mgper 2 Packet(s)DSLD:6220
Dr. BergCod Liver Oil Capsules50 mgper 3 Capsule(s)DSLD:316054
Dr. Clark StoreOmega-3 1000 mg172 mgper 1 Softgel(s)DSLD:220015
Dr. LaMar's ProductsOmega3420 mgper 2 Capsule(s)DSLD:180401
Dr. SinatraOmega Q Plus 100350 mgper 2 Softgel(s)DSLD:239716
Dr. Stan GubermanUltimate Joint Repair Platinumamount not statedper 4 Capsule(s)DSLD:33067
Dr. Stan GubermanUltimate Omega240 mgper 1 Softgel(s)DSLD:33066
Dr. TobiasOptimum Omega 3 Fish Oil Triple Strength600 mgper 2 Softgel(s)DSLD:73062
Elevation HealthKrill Oil60 mgper 1 Gelcap(s)DSLD:37474
Endo-met LaboratoriesEPA-DHA90 mgper 1 Softgel(s)DSLD:229075
Endo-met LaboratoriesEPA-DHA90 mgper 1 Softgel(s)DSLD:229079
Esmond Natural180/120 Fish Oil 1000 mg120 mgper 1 Softgel(s)DSLD:178602
EstrovenStay SharpAlgal Oil400 mgper 2 Softgel(s)DSLD:278648
Evlution NutritionFish Oil 1250 mg300 mgper 1 Softgel(s)DSLD:239648
Evlution NutritionOmega-3 Fish Oil 1250 mg300 mgper 1 Softgel(s)DSLD:326405
Exeltis USADHA Softgel CapsuleAlgal Oil, Natural250 mgper 1 Softgel Capsule(s)DSLD:304794
Finest NaturalFish Oil Mini-Gels Regular Strength 600 mg108 mgper 1 Softgel(s)DSLD:25940
Finest NaturalFish Oil Triple Strength 1400 mg253 mgper 1 Softgel(s)DSLD:13190
Finest NaturalMen's 50+ AdvancedDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-316 mgper 1 Capsule(s)DSLD:13254
Finest NutritionCod Liver Oil 415 mg36 mgper 1 Softgel(s)DSLD:207018
Finest NutritionDHA 900 mgAlgal Microalgae Oil900 mgper 1 Softgel(s)DSLD:273795
Finest NutritionDouble Strength Fish Oil 1200 mgDHA Note: Omega Fatty Acids216 mgper 1 Softgel(s)DSLD:207283
Finest NutritionFish Oil + D3216 mgper 1 Softgel(s)DSLD:65365
FitLineGeneration 50+113 mgper 5 Gram(s)DSLD:321592
FloraDHA Vegetarian Algae500 mgper 2 Capsule(s)DSLD:265450
Fresh NutritionFish OilOmega-3 DHA (Alt. Name: Docosahexaenoic Acid)120 mgper 2 Softgel Capsule(s)DSLD:241928
Garden of Life BabyPlant DHA Liquidtriglyceride form600 mgper 0.5 mLDSLD:321372
Garden of Life Dr. FormulatedPrenatal Multi + DHADHA (Form: Triglyceride form) (Alt. Name: Docosahexaenoic Acid)400 mgper 1 Softgel(s)DSLD:242666
Gaspari NutritionOmega-3 2400 mgOmega-3 Docosahexaenoic Acid (Alt. Name: DHA)720 mgper 1 Softgel(s)DSLD:223186
Genestra BrandsSuper EFA Liquid Natural Orange Flavor725 mgper 2.5 mLDSLD:176640
GesticareDHA CapsuleAlgal Oil · Docosahexaenoic Acid (Form: from Algal Oil) (Alt. Name: DHA)250 mgper 1 Gelatin Capsule(s)DSLD:43186
GNCCod Liver Oil100 mgper 1 Softgel Capsule(s)DSLD:328783
GNCDHA 600omega-3600 mgper 1 Softgel Capsule(s)DSLD:305831
GNCTriple Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3360 mgper 1 Yellow Softgel Capsule(s)DSLD:44713
GNC Beyond RawTriple Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3360 mgper 1 Yellow Softgel Capsule(s)DSLD:63775
GNC Mega MenConcentrated Mini Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3144 mgper 1 Yellow Softgel Capsule(s)DSLD:27472
GNC Mega MenDouble Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3240 mgper 1 Light Yellow Softgel Capsule(s)DSLD:33551
GNC Mega MenDouble Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3240 mgper 1 Softgel(s)DSLD:3554
GNC Mega MenDouble Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3240 mgper 1 Softgel(s)DSLD:5893
GNC Mega MenDouble Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega 3240 mgper 1 Light Yellow Softgel Capsule(s)DSLD:66736
GNC Mega MenFish Oil with CoQ-10DHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3240 mgper 1 Softgel(s)DSLD:15716
GNC Mega MenFish Oil with CoQ-10240 mgper 1 Green Softgel Capsule(s)DSLD:33634
GNC Mega MenHeart & Eye HealthDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3360 mgper 1 Softgel(s)DSLD:220279
GNC Mega MenHigh Potency Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3360 mgper 1 Softgel(s)DSLD:219870
GNC Mega MenMemoralFish Oil · DHA (Form: as Fish Body Oil) (Alt. Name: Docosaehexaenoic Acid, Omega 3)75 mgper 1 Softgel(s)DSLD:15717
GNC Mega MenMemorallFish Oil · DHA (Form: as Fish Body Oil) (Alt. Name: Docosahexaenoic Acid) Note: Omega-375 mgper 1 Dark Brown Softgel Capsule(s)DSLD:33652
GNC Mega MenTriple Strength Fish oilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3360 mgper 1 Amber Softgel(s)DSLD:19430
GNC Mega MenTriple Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3253 mgper 1 Softgel(s)DSLD:3560
GNC MilestonesConcentrated Mini Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3144 mgper 1 Yellow Softgel Capsule(s)DSLD:65759
GNC MilestonesConcentrated Mini Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3144 mgper 1 Yellow Softgel Capsule(s)DSLD:65775
GNC Preventive NutritionBlood Pressure FormulaDHA Note: Omega-3140 mgper 2 Softgel(s)DSLD:1634
GNC Preventive NutritionEye Health FormulaFish Oil · fish body200 mgper 2 Softgel Capsule(s)DSLD:304446
GNC Preventive NutritionFish Oil With PolysterolsDocosahexaenoic Acid Note: Omega-3126.5 mgper 1 Softgel(s)DSLD:3534
GNC Preventive NutritionMemorallFish Oil · DHA (Form: as Fish Body Oil) (Alt. Name: Docosahexaenoic Acid)150 mgper 2 Softgel(s)DSLD:1837
GNC Preventive NutritionMulti-OilDHA - omega-3 (Alt. Name: Docosahexaenoic Acid)120 mgper 3 Soft Gel Capsule(s)DSLD:1838
GNC Preventive NutritionTriple Strength Fish OilDHA Note: Omega-3253 mgper 1 Softgel(s)DSLD:3519
GNC Pro Performance AMPTriple Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3253 mgper 1 Softgel Capsule(s)DSLD:45113
GNC SelectFish Oil100 mgper 1 Softgel(s)DSLD:313698
GNC SelectOmega 3-6-9 LemonOmega-3 Fatty Acids120 mgper 3 Softgel(s)DSLD:313699
GNC Total LeanPremium CLA 3-6-9Fish Oil Concentrate · DHA (Form: from Fish Oil concentrate) (Alt. Name: Docosahexaenoic Acid) Note: Omega 358 mgper 2 Softgel(s)DSLD:213499
GNC Total LeanPremium CLA ComplexFish Oil · DHA (Form: from Fish Body Oil, Omega-3) (Alt. Name: Docosahexaenoic Acid)58 mgper 2 Softgel(s)DSLD:27243
GNC Total Lean AdvancedPremium CLA 3-6-9Fish Oil · DHA (Form: from Fish Oil) (Alt. Name: Docosahexaenoic Acid) Note: Omega-358 mgper 2 Softgel(s)DSLD:74477
GNC Triple StrengthFish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3253 mgper 1 Softgel(s)DSLD:1024
GNC Triple StrengthFish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3253 mgper 1 Softgel(s)DSLD:219248
GNC Triple StrengthFish Oil + Vitamin D-3DHA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3 DHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3253 mgper 1 Softgel(s)DSLD:830
GNC Triple StrengthFish Oil +Co Q-10DHA Note: Omega-3253 mgper 1 Softgel(s)DSLD:831
GNC Triple StrengthFish Oil +KrillDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3253 mgper 2 Softgel(s)DSLD:1073
GNC Triple StrengthFish Oil +ResveratrolDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3253 mgper 1 Softgel(s)DSLD:1071
GNC Triple StrengthFish Oil SportDHA Note: Omega-3253 mgper 2 Softgel(s)DSLD:1651
GNC Triple StrengthOmega ComplexDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3253 mgper 3 Softgel(s)DSLD:1050
GNC Ultra Mega GreenOmega ComplexDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-384.4 mgper 1 Softgel(s)DSLD:11609
GNC Women'sAlgae-Based DHA 200Marine Microalgae Oil · DHA (Form: as Marine Microalgae Oil) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Capsule(s)DSLD:214885
GNC Women'sFish Body OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3360 mgper 1 Amber Softgel Capsule(s)DSLD:243671
GNC Women'sMultivitamin Prenatal Plus DHA & IronFish Oil · DHA (Form: from Fish Body Oil) (Alt. Name: Docosahexaenoic Acid)500 mgper 3 Softgel(s)DSLD:229141
GNC Women'sPrenatal DHAMarine Algae Oil · DHA (Form: from Marine Algae Oil Genus: Schizochytrium Species: Sp.)300 mgper 1 Softgel Capsule(s)DSLD:27245
GNC Women'sPrenatal Formula With DHA500 mgper 3 Softgel Capsule(s)DSLD:75159
GNC Women'sPrenatal With DHA500 mgper 3 Softgel Capsule(s)DSLD:81932
GNC Women's Ultra MegaConcentrated Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3144 mgper 1 Yellow Softgel Capsule(s)DSLD:42241
GNC Women's Ultra MegaConcentrated Mini Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3144 mgper 1 Yellow Softgel Capsule(s)DSLD:33540
GNC Women's Ultra MegaDouble Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3240 mgper 1 Yellow Softgel Capsule(s)DSLD:83088
GNC Women's Ultra MegaFish Oil With CoQ10DHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3240 mgper 1 Green Softgel Capsule(s)DSLD:33505
GNC Women's Ultra MegaHeart & Eye HealthDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega 3360 mgper 1 Amber Softgel(s)DSLD:69499
GNC Women's Ultra MegaMemorallFish Oil · DHA (Form: as Fish Body Oil) (Alt. Name: Docosahexaenoic Acid) Note: Omega-375 mgper 1 Dark Brown Softgel Capsule(s)DSLD:33514
GNC Women's Ultra MegaTriple Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3360 mgper 1 Capsule(s)DSLD:19466
GNC Women's Ultra MegaTriple Strength Fish OilDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3253 mgper 1 Softgel(s)DSLD:5895
Gottfried InstituteHormone Balancing EssentialsFish Oil · DHA (Form: from Fish Oil) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Packet(s)DSLD:45504
Greens First FemalePrenatal with Vegan DHA plus ProbioticsDocosahexaenoic Acid250 mgper 3 Capsule(s)DSLD:312851
Guardian HealthKids Vita Plus Natural Orange Flavor0.5 mgper 1 Tablet(s)DSLD:299124
HBC ProtocolsOmega Complex120 mgper 3 Softgel(s)DSLD:74974
Health From The SunDHA From Algae OilMicroalgae Oil · Docosahexaenoic Acid (Form: from vegan Microalgae Oil) (Alt. Name: DHA)200 mgper 1 Softgel(s)DSLD:47579
Health From The SunEye FormulaFish210 mgper 3 Capsule(s)DSLD:45872
Health From The SunVegan Omega-3 DHAMarine Microalgae Oil · DHA (Form: From vegan microalgae oil) (Alt. Name: Docosahexaenoic Acid) Note: omega-3200 mgper 1 Vegetarian Softgel(s)DSLD:34359
HerbadietOmega 3 (DHA + EPA)Standardized to contain min 6% DHA400 mgper 2 Capsule(s)DSLD:257823
HerbadietOmega 3 (DHA + EPA)Standardized to contain min 6% DHA200 mgper 1 Capsule(s)DSLD:293585
HerbadietOmega 3 (DHA + EPA) PowderStandardized to contain min 6% DHA200 mgper 500 mgDSLD:293637
Herbalife NutritionCoQ10 PlusAlgal Oil100 mgper 1 Softgel(s)DSLD:335015
HerblifeCore ComplexAlgal Oil100 mgper 1 Packet(s)DSLD:335016
HerbTonicsTriglyceride Form Omega-3 2500 mg Lemon Flavored600 mgper 2 Soft Gel(s)DSLD:287069
High Performance NutritionN(4)810 mgper 3 Softgel(s)DSLD:271158
Higher NatureComplete Omegas 3:6:7:9480 mgper 4 Capsule(s)DSLD:228412
Higher NatureComplete Omegas 3:6:7:9120 mgper 1 Capsule(s)DSLD:240570
Higher NatureComplete Omegas 3:6:7:9480 mgper 4 Capsule(s)DSLD:245644
Higher NatureComplete Omegas 3:6:7:9480 mgper 4 Capsule(s)DSLD:245645
Higher NatureComplete Omegas 3:6:7:9480 mgper 4 Capsule(s)DSLD:245653
Higher NatureComplete Omegas 3:6:7:9480 mgper 4 Capsule(s)DSLD:41470
Higher NatureComplete Omegas 3:6:7:9480 mgper 4 Capsule(s)DSLD:41474
Higher NatureComplete Omegas 3:6:7:9480 mgper 4 Capsule(s)DSLD:41475
Higher NatureComplete Omegas 3:6:7:9480 mgper 4 Capsule(s)DSLD:41485
Higher NatureEssential Omegas 3:6:7:9120 mgper 1 Capsule(s)DSLD:42576
Higher NatureKeep Sharp253 mgper 1 Jelly(s)DSLD:178205
Higher NatureLemon Fish Oil460 mgper 2.5 mLDSLD:217005
Higher NatureOmega 3 Fish Oil 1000 mg120 mgper 1 Softgel Capsule(s)DSLD:40716
Higher NatureOmega 3 Fish Oil 1000 mg120 mgper 1 Softgel Capsule(s)DSLD:40930
Higher NatureOmega 3 Fish Oil 1000 mg120 mgper 1 Softgel Capsule(s)DSLD:40933
Higher NatureSuper Potency Fish Oil250 mgper 1 Capsule(s)DSLD:246034
Higher NatureSuper Potency Fish Oil250 mgper 1 Softgel Capsule(s)DSLD:304553
Higher NatureVisualeyes25 mgper 1 Capsule(s)DSLD:245906
Higher NatureVisualeyes25 mgper 1 Capsule(s)DSLD:240563
Higher NatureVisualeyes25 mgper 1 Capsule(s)DSLD:304558
Higher Nature KidsSmart Focus Intensely Fruity Flavoured Jellies100 mgper 1 Jelly(s)DSLD:216996
Highland LaboratoriesMy PrenatalDHA (Alt. Name: Docosahexaenoic Acid) Note: vegetarian90 mgper 4 Capsule(s)DSLD:80016
HMS NutritionLactation Support10 mgper 2 Capsule(s)DSLD:229872
HoltraCeuticalsUltra Omega300 mgper 1 Softgel(s)DSLD:19884
i-HealthDHA SoftgelAlgal Oil · Antioxidants [Tocopherols and Ascorbyl Palmitate]350 mgper 1 DHA Softgel(s)DSLD:182727
IM8Daily Ultimate Longevity + Healthy AgingAlgae · omega-3 fatty acid200 mgper 1 Capsule(s)DSLD:333263
Indiana Botanic GardensRed Krill Oil 500 mg22:6 - DHA5 mgper 1 Softgel(s)DSLD:46982
Innovative Apothecary SolutionsMulti ProAlgae315 mgper 1 Capsule(s)DSLD:263602
Integrative TherapeuticsVitaline Neuro-Essentials5 mgper 2 Caplet(s)DSLD:24221
Iron-TekEssential Muscle LipidsFish Oil Concentrate · Docosahexaenoic Acid (Form: from Fish Oil Concentrate (Form: Anchovy, Mackerel, Sardine)) (Alt. Name: DHA)160 mgper 2 Softgel(s)DSLD:2918
Irwin KidsOmega-3 Citrus-Chews Super Citrus Soft ChewsFish Oil · DHA (Form: from Fish Oil) (Alt. Name: Docosahexaenoic Acid) Note: omega-3 fatty acid42 mgper 1 Soft Chew(s)DSLD:45699
John Gilmore, MDHeart Smart Fish Oil Softgels300 mgper 1 Softgel(s)DSLD:267848
JuvenonEssential Omega-3400 mgper 2 Softgel(s)DSLD:261896
KidzPlayBrainy PlayDHA Note: 18.3 mg118.3 mgper 1 mLDSLD:22250
KirkmanAll Natural Cod Liver Oil Liquid250 mgper 0.5 Teaspoon(s)DSLD:23981
KirkmanAll Natural Cod Liver Oil Liquid250 mgper 0.5 Teaspoon(s)DSLD:23986
KirkmanCod Liver Oil Liquid150 mgper 2.5 mLDSLD:259995
KirkmanCod Liver Oil Liquid Natural Lemon Lime Flavor150 mgper 2.5 mLDSLD:317718
Krill Doctor ProfessionalKrill Omega-390 mgper 2 Softgel(s)DSLD:175022
Lake Avenue NutritionDHA from Marine Algae 200 mgAlgal Oil200 mgper 1 Softgel(s)DSLD:272337
Leading Edge HealthBrainPillOmega-3 Fish Oil powder · DHA 15%100 mgper 1 Capsule(s)DSLD:280518
LifeVegetarian Algae DHA200 mgper 1 Vegetarian Softgel(s)DSLD:39528
Life ExtensionOmega-3 Lemon Whirl422 mgper 1 TbspDSLD:58974
Life ExtensionOmega-3 Tropical Whirl422 mgper 1 TbspDSLD:58979
Life ExtensionPrenatal AdvantageAlgae Oil200 mgper 1 Softgel(s)DSLD:328644
Life ExtensionVegetarian DHAAlgae Oil · DHA (Form: from Algae Oil Genus: Schizochytrium Species: sp.) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Vegetarian Softgel(s)DSLD:232135
Life NutritionBaby Algae DHA100 mgper 1 Softgel(s)DSLD:206166
Life's DHABrainstrong AdultAlgal Oil · DHA Note: docosahexaenoic acid from algal oil900 mgper 3 Softgel(s)DSLD:2493
Life's DHALife's DHA AdultAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Softgel(s)DSLD:242624
Life's DHALife's DHA KidsAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Softgel(s)DSLD:242622
Life's DHALife's DHA Kids & TeensAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Softgel(s)DSLD:242620
Living FuelSuper Essentials Omegas 3EDA+Fish Oil · DHA (Form: from purified Fish Oils) (Alt. Name: Docosahexanoic Acid) Note: 22:6 Omega 3120 mgper 1 Softgel(s)DSLD:282561
Martin Avenue PharmacyBrain Health Support With Ginkgo Biloba & Phosphatidyl SerineDHA powder (Alt. Name: docosahexaenoic acid) Note: From Neuromins(TM) a highly purified source of DHA from microalgae.100 mgper 2 Tablet(s)DSLD:18812
Martin Avenue PharmacyDHA 100 mgMicroalgae Oil · DHA (Form: from microalgae oil) (Alt. Name: docosahexaenoic acid) Note: Neuromins(TM) is a highly-purified source of DHA from microalgae. It is produced under strict quality control conditions and is free of chemical pollutants and toxins.100 mgper 1 Capsule(s)DSLD:19074
Mary Ruth'sOrganic Women's Multivitamin Liposomal Vanilla PeachAlgal Oil · Omega-3100 mgper 15 Milliliter(s)DSLD:327734
Mary Ruth'sOrganic Women's Multivitamin Liposomal Vanilla PeachAlgal Oil · Omega-3100 mgper 15 Milliliter(s)DSLD:327735
Mary Ruth'sTurmeric & DHA Liposomal Orange GingerAlgal Oil · omega-3210 mgper 15 mLDSLD:327736
Mason NaturalNorwegian Salmon Oil 2000 mg220 mgper 2 Softgel(s)DSLD:244788
Mason NaturalSugar-Free Prenatal Multivitamin with DHA & ZincAlgae Oil, Powder · DHA (Form: from Algae Oil) (Alt. Name: Docosahexanoic Acid)50 mgper 3 Gummy(ies)DSLD:244892
Maxi HealthMaxi-Omega-3 Concentrate460 mgper 2 Softgel(s)DSLD:295567
MeijerOnce Daily Prenatal MultiSchizochytrium sp. Oil · Omega-3200 mgper 1 Softgel(s)DSLD:296587
Mental RefreshmentKrill Oil 1000 mg130 mgper 2 Capsule(s)DSLD:247641
MetagenicsMetaKids Nutrition Powder Chocolate Flavor75 mgper 29 Gram(s)DSLD:216415
MetagenicsMetaKids Nutrition Powder Vanilla Flavor75 mgper 27 Gram(s)DSLD:295766
MetagenicsPlusOne1 Gram(s)per 1 Packet(s)DSLD:216819
MetagenicsWellness Essentials Brain HealthDHA (Form: Docosahexaenoic Acid Triglyceride)750 mgper 1 Packet(s)DSLD:211103
Method PharmaceuticalsDothelle DHA Softgels156 mgper 1 Capsule(s)DSLD:263294
Mission Pharmacal CitraNatalCitraNatal 90 DHA 300 mg DHA Soft GelAlgal Oil · Docosahexaenoic Acid (Form: from 750 mg 40% Algal Oil) (Alt. Name: DHA)300 mgper 1 Softgel(s)DSLD:240145
Mission Pharmacal CitraNatalCitranatal 90 DHA Gelatin Capsule300 mgper 1 Gelatin Capsule(s)DSLD:45458
Mission Pharmacal CitraNatalCitraNatal 90 DHA Gelatin Capsule300 mgper 1 Gelatin Capsule(s)DSLD:63755
Mission Pharmacal CitraNatalCitranatal 90 DHA Soft GelAlgal Oil · Docosahexaenoic Acid (Form: from 750 mg 40% Algal Oil) (Alt. Name: DHA)300 mgper 1 Softgel(s)DSLD:215339
Mission Pharmacal CitraNatalCitraNatal Assure 300 mg DHA Soft GelAlgal Oil · Docosahexaenoic Acid (Form: from 750 mg 40% Algal Oil) (Alt. Name: DHA)300 mgper 1 Softgel(s)DSLD:206922
Mission Pharmacal CitraNatalCitraNatal Assure DHA Capsule300 mgper 1 Capsule(s)DSLD:37182
Mission Pharmacal CitraNatalCitraNatal Assure DHA Gelatin CapsuleDocosahexaenoic Acid (Alt. Name: DHA) Note: 40% from300 mgper 1 Capsule(s)DSLD:63989
Mission Pharmacal CitraNatalCitraNatal Assure DHA Soft GelAlgal Oil · Docosahexaenoic Acid (Form: from 750 mg 40% Algal Oil) (Alt. Name: DHA)300 mgper 1 Softgel(s)DSLD:215277
Mission Pharmacal CitraNatalCitraNatal Assure DHA Soft Gel300 mgper 1 Softgel(s)DSLD:304787
Mission Pharmacal CitraNatalCitraNatal DHA Gelatin Capsule250 mgper 1 Gelatin Capsule(s)DSLD:45465
Mission Pharmacal CitraNatalCitraNatal DHA Soft GelAlgal Oil · Docosahexaenoic Acid (Form: from 750 mg 40% Algal Oil) (Alt. Name: DHA)300 mgper 1 Softgel(s)DSLD:241671
Mission Pharmacal CitraNatalCitraNatal Essence DHA Soft GelAlgal Oil · Docosahexaenoic Acid (Form: from 750 mg 40% Algal Oil) (Alt. Name: DHA)300 mgper 1 Softgel(s)DSLD:232435
Mission Pharmacal CitraNatalCitraNatal Harmony250 mgper 1 Capsule(s)DSLD:12884
Mission Pharmacal CitraNatalCitraNatal HarmonyAlgal Oil · Docosahexaenoic Acid (Form: from 650 mg 40% Algal Oil) (Alt. Name: DHA)260 mgper 1 Soft Gel(s)DSLD:215317
Mission Pharmacal CitraNatalCitraNatal HarmonyDocosahexaenoic Acid (Alt. Name: DHA) Note: 40% from260 mgper 1 Capsule(s)DSLD:43173
Mission Pharmacal CitraNatalCitraNatal MedleyAlgal Oil · Docosahexaenoic Acid (Form: from 377 mg 53% Algal Oil) (Alt. Name: DHA)200 mgper 1 Softgel(s)DSLD:205154
MN Morphogen NutritionNutrigen Cranberry AppleAlgae · Vegan Algae Source Providing 250mg DHA2,500 mgper 27 Gram(s)DSLD:261187
Morphogen NutritionNutrigen Pineapple PunchDocosahexaenoic Acid (Form: providing 250 mg DHA) (Alt. Name: DHA) Note: (vegan algae source) (10%)2,500 mgper 24.5 Gram(s)DSLD:212764
Mountain Meadow HerbsKrill Oil 1200 mg80 mgper 1 Softgel(s)DSLD:267493
MRI PerformanceOmega 3omega-3253 mgper 1 Softgel(s)DSLD:313484
MRMFresh Omega Extra Virgin Norwegian Salmon Oil60 mgper 1 Fish softgel(s)DSLD:178447
MusclePharmFish Oil300 mgper 1 Soft Gel(s)DSLD:17995
MuscleSportLipoSlim for HerDeep Sea Cold Water Fish Oil Complexamount not statedper 2 Softgel(s)DSLD:256919
Natural Cell SupplementsOmegaActiv288 mgper 1 Softgel(s)DSLD:317955
Natural ClinicianClinical CognitionTuna · DHA (Form: Docosahexaenoic Acid (Form: from tuna fish))30 mgper 1 Capsule(s)DSLD:18615
Natural ClinicianClinical EPA/DHA ForteDHA (Alt. Name: Docosahexaenoic Acid) Note: Targeted Delivery for enhanced absorption and bioactivity.400 mgper 1 Softgel(s)DSLD:18623
Natural Health Improvement CenterEnteric Coated Fish Oil340 mgper 2 Softgel(s)DSLD:71195
Natural NutraKrill Oil37.5 mgper 1 Softgel(s)DSLD:246973
Nature's BountyHeart Health Support Packamount not statedper 1 Packet(s)DSLD:3788
Nature's BountyPrenatal Multi Healthy MomAlgal · Docosahexaenoic Acid (Form: from DHA rich oil derived from a plant based algae Schizochytrium sp. Genus: Schizochytrium Species: sp.) (Alt. Name: DHA)200 mgper 2 Softgel(s)DSLD:240159
Nature's Bounty Optimal SolutionsHealthy Mom Prenatal MultiAlgal · Docosahexaenoic Acid (Form: from DHA rich oil derived from a plant based algae Schizochytrium sp. Genus: Schizochytrium Species: sp.) (Alt. Name: DHA)200 ngper 2 Softgel(s)DSLD:308222
Nature's Bounty Optimal SolutionsVegetarian DHA 200 mgAlgal · Docosahexaenoic Acid (Form: from DHA rich oil derived from a plant based algae Schizochytrium sp. Genus: Schizochytrium Species: sp.) (Alt. Name: DHA)200 mgper 1 Softgel(s)DSLD:29296
Nature's CraftKids Multivitamin Drops Orange FlavorAlgae50 mgper 1 mLDSLD:296785
Nature's LifeOmega 3 EFA Complex360 mgper 3 Softgel(s)DSLD:47347
Nature's NutraVegetarian DHA for KidsAlgal Oil100 mgper 1 mLDSLD:318826
Nature's WayAlive! Complete Premium Prenatal MultivitaminAlgal Oil200 mgper 2 Softgel(s)DSLD:304619
Nature's WayAlive! Premium Prenatal Gummies Strawberry & Lemon FlavoredAlgal Oil75 mgper 3 Gummy(ies)DSLD:332156
Nature's WayAlive! Prenatal Multivitamin GummyAlgal Oil50 mgper 2 Gummy(ies)DSLD:327866
Nature's WayCompletia Prenatal Multi-Vitamin25 mgper 2 Tablet(s)DSLD:230198
Nature's WayCompletia Prenatal Multi-VitaminTuna25 mgper 2 Tablet(s)DSLD:56163
Nature's WayCompletia Prenatal Multi-VitaminTuna50 mgper 2 Tablet(s)DSLD:66513
Nature's WayEfaGold NeurominsAlgal Microalgae Oil · Docosahexaenoic Acid (Form: from Algal Microalgae Oil) (Alt. Name: DHA)200 mgper 1 Softgel(s)DSLD:79297
Nature's WayEfaGold Neuromins 100 mg DHAAlgal Microalgae Oil · Docosahexaenoic Acid (Form: from Algal Microalgae (Schizochytrium spp.) oil Genus: Schizochytrium Species: spp.) (Alt. Name: DHA)100 mgper 1 Softgel(s)DSLD:63622
Nature's WayNeurominsAlgal Microalgae Oil · Docosahexaenoic Acid (Form: from Algal Microalgae (Schizochytrium spp.) oil Genus: Schizochytrium Species: spp.) (Alt. Name: DHA)100 mgper 1 Softgel(s)DSLD:230015
Nature's WayNeurominsAlgal Microalgae Oil200 mgper 1 Softgel(s)DSLD:304679
Natures CraftOmega-3 Fish Oil 1200 mg288 mgper 1 Softgel(s)DSLD:256575
NatureSmartDisney Monsters University Multi-Vitamin GummiesFish Oil · DHA (Form: from Fish Oil) (Alt. Name: Docosahexaenoic Acid)50 mcgper 1 Gummy(ies)DSLD:71459
NatureSmartDisney My First Gummies Multi VitaminFish Oil · DHA (Form: from Fish Oil) (Alt. Name: Docosahexaenoic Acid)100 mcgper 2 Gummy(ies)DSLD:12265
NatureSmartDisney Princess Complete MultiVitaminFish Oil · DHA (Form: from Fish Oil) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Tablet(s)DSLD:26529
NatureSmartDisney Tinkerbell Multi-Vitamin GummiesFish Oil · DHA (Form: from Fish Oil) (Alt. Name: Docosahexaenoic Acid)100 mcgper 1 Gummy(ies)DSLD:71425
NatureSmartGummies MultivitaminFish Oil · DHA (Form: from Fish Oil) (Alt. Name: Docosahexaenoic Acid)100 mcgper 2 Gummie(s)DSLD:26536
NaturesPlusOmega Krill Oil 600 mg35 mgper 1 Liquid-Filled Capsule(s)DSLD:298566
NaturesPlusPro Creation Female Fertility Supportfrom Algae of Schizochytrium sp. · vegetarian16 mgper 2 Capsule(s)DSLD:298597
NatureWiseMultivitamin & Minerals Prenatal CompleteDocosahexaenoic Acid20 mgper 2 Capsule(s)DSLD:327751
NCBAlaska Deep Sea Fish Oil240 mgper 2 Softgel(s)DSLD:13732
Nested NaturalsVegan Omega-3Algal Oil250 mgper 1 Vegan Capsule(s)DSLD:286825
Neurohacker CollectiveQualia MindAlgae · DHA (Form: from Algae) (Alt. Name: Docosahexaenoic Acid)80 mgper 7 Vegetarian Capsule(s)DSLD:258978
Neurohacker CollectiveQualia MindAlgae80 mgper 7 Vegetarian Capsule(s)DSLD:267666
Neurohacker CollectiveQualia MindAlgae80 mgper 7 Capsule(s)DSLD:314263
Neurohacker CollectiveQualia Mind Caffeine FreeAlgae · DHA (Form: from Algae) (Alt. Name: Docosahexaenoic Acid)80 mgper 7 Vegetarian Capsule(s)DSLD:239667
New AgeFish Oil 2500 mg682 mgper 2 Softgel(s)DSLD:268645
Noor VitaminsPre & Post Natal DHA + Iron Fruit FlavoredAlgal Oil · Docosahexaenoic Acid (Form: from Algal Oil) (Alt. Name: DHA)75 mgper 3 Gummie(s)DSLD:183318
Nordic NaturalsChildren's DHA Strawberry255 mgper 2.5 mLDSLD:214259
Nordic NaturalsChildren's DHA Strawberry255 mgper 2.5 mLDSLD:277314
North American Herb & SpicePurelyPak95 mgper 7.3 Gram(s)DSLD:270080
North American Herb & SpicePurelyPak126 mgper 7.3 Gram(s)DSLD:307960
NOWDouble Strength DHA-500amount not statedper 1 Softgel(s)DSLD:314277
NOWVegetarian DHA400 mgper 2 Softgel(s)DSLD:36617
Nutra SportPerformance Omega-3350 mgper 1 Softgel(s)DSLD:319228
NutraChampsOmega 3 Fish Oil 3,600 mg Natural Lemon Flavor864 mgper 3 Softgel(s)DSLD:228956
NutraKeyFish Oil 1000 mg120 mgper 1 Softgel(s)DSLD:287400
Nutri-RichMini Me DHA 100 mgAlgae Oil, Powder · DHA (Form: from Algae Oil) (Alt. Name: Docosahexanoic Acid)100 mgper 1 Softgel(s)DSLD:176524
Nutri-RichMini Me DHA 100 mgAlgae Oil, Powder · DHA (Form: from Algae Oil) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Softgel(s)DSLD:214111
Nutri-RichPrenatal Multi+DHAAlgae Oil, Powder · DHA (Form: from Algae Oil) (Alt. Name: Docosahexanoic Acid)200 mgper 1 Softgel(s)DSLD:176556
Nutri-RichUltra EPA + DHA 1,000 mg250 mgper 2 Softgel(s)DSLD:176515
Nutri-RichUltra EPA + DHA 1,000 mg250 mgper 2 Softgel(s)DSLD:214108
Nutri-WestComplete Hi-Potency Omega-3 LiquidFish · DHA (Form: contains Fish) (Alt. Name: Docosahexaenoic Acid)800 mgper 1 Teaspoon(s)DSLD:27617
NutriCologySuper Immuno Complex240 mgper 1 Packet(s)DSLD:183928
NutricostJoint Complex 1490 mg50 mgper 2 Capsule(s)DSLD:77150
NutriSuppzSuper Krill Oil Complex 500 mg105 mgper 1 Softgel(s)DSLD:268894
OL Olympian LabsKrill Oil 1000 mg90 mgper 2 Softgel(s)DSLD:326661
OL Olympian LabsKrill Oil 1000 mg90 mgper 2 Softgel(s)DSLD:326672
OL Olympian LabsKrill Oil 500 mg45 mgper 1 Softgel(s)DSLD:175745
OL Olympian LabsNorwegian Salmon Oil240 mgper 3 Softgel(s)DSLD:9738
OL Olympian LabsPrenatal Complex3 mgper 1 Capsule(s)DSLD:67155
OmegaWorksDelicious Omega 3 Liquid Formula500 mgper 1 tspDSLD:7686
OmegaWorksSuper Omega 3200 mgper 1 Softgel(s)DSLD:259729
OraNothing Fishy Here. Fresh Orange Flavor600 mgper 1 mLDSLD:183945
Orphic NutritionOmega 3 Fish Oil 2160 mg864 mgper 1 Softgel(s)DSLD:285532
Ortho Molecular ProductsOrthomega Select DHA580 mgper 1 Softgel Capsule(s)DSLD:174227
Ortho Molecular ProductsOrthomega Select EPA60 mgper 1 Softgel Capsule(s)DSLD:174221
Ortho Molecular ProductsPrenatal Complete with DHA580 mgper 3 Capsule(s)DSLD:175696
PerqueEPA/DHA Guard500 mgper 2 Softgel(s)DSLD:240750
PerqueEPA/DHA Guard500 mgper 2 Softgel(s)DSLD:240753
PerqueEPA/DHA Guard Softgels500 mgper 2 Softgel(s)DSLD:18732
PerqueEPA/DHA Guard Softgels500 mgper 2 Softgel(s)DSLD:18733
PharmaPure RxPNV OB+DHA Softgel250 mgper 1 Softgel(s)DSLD:37180
PharmaxBerry Frutol375 mgper 10 mLDSLD:238900
PharmaxCardol210 mgper 1 tspDSLD:55422
PharmaxDHA TasteBurst Natural Orange Flavor130 mgper 2 Chewable Soft Gel(s)DSLD:55433
PharmaxFinest Pure Cod Liver Oil466 mgper 0.5 tspDSLD:55776
PharmaxFinest Pure Fish Oil725 mgper 0.5 tspDSLD:176136
PharmaxFinest Pure Fish Oil725 mgper 0.5 tspDSLD:55813
PharmaxFinest Pure Fish Oil625 mgper 1 tspDSLD:70995
PharmaxFinest Pure Fish Oil Capules375 mgper 2 Capsule(s)DSLD:55371
PharmaxFinest Pure Fish Oil Plus CoQ10 Natural Orange Flavor710 mgper 1 tspDSLD:55432
PharmaxFinest Pure Krill Oil70 mgper 2 Capsule(s)DSLD:55436
PharmaxFrutol187.5 mgper 1 tspDSLD:55369
PharmaxFrutol with Full Spectrum Multivitamins172.5 mgper 1 tspDSLD:55787
PharmaxHigh DHA Berry Frutol600 mgper 2 tspDSLD:55391
PharmaxHigh DHA Omega-3 Fatty AcidsTuna Oil · Docosahexaenoic acid (Form: provided as Tuna oil) (Alt. Name: DHA)200 mgper 1 Softgel Capsule(s)DSLD:70981
PharmaxHigh EPA Finest Pure Fish Oil Natural Orange Flavor320 mgper 1 tspDSLD:55431
PharmaxOmega-3 Fatty Acids265 mgper 1 Capsule(s)DSLD:55838
PharmaxOmega-3 Fatty Acids265 mgper 1 Capsule(s)DSLD:55888
PharmaxOmega-3 Fatty Acids265 mgper 1 Capsule(s)DSLD:56157
PharmaxOmega-3 Fatty Acids265 mgper 1 Softgel(s)DSLD:70941
PharmaxOmega-3 Fatty Acids265 mgper 1 Softgel(s)DSLD:71006
Pharmaxa LabsProvasil5 mgper 1 Tablet(s)DSLD:306938
Physician's StrengthPotentPak126 mgper 7.3 Gram(s)DSLD:268772
Phyto ParisPhytophanere2 mgper 2 Caplet(s)DSLD:206205
Pink StorkPrenatal Plus DHA200 mgper 2 Capsule(s)DSLD:216949
PlexusMegaKids Microbiome Tropical PunchMarine Algae Oil50 mgper 1 Stick(s)DSLD:317543
PNV Prenatal HealthDHA MiniCaps250 mgper 1 MiniCap(s)DSLD:241348
Premier Research LabsPremier DHAAlgal Oil200 mgper 1 Softgel(s)DSLD:269251
Primal HarvestPrimal Omega-3400 mgper 2 Softgel(s)DSLD:277139
Primal PharmOMEGA288 mgper 1 Softgel(s)DSLD:276404
Priority One Nutritional SupplementsComplete One Daily5%42 mgper 1 Capsule(s)DSLD:277352
ProceraOmega-3288 mgper 1 Softgel(s)DSLD:293227
Progressive Professional from Progressive LaboratoriesBrilliant Vision with Seanol-P100 mgper 3 Vegetable Capsule(s)DSLD:261438
Progressive Professional from Progressive LaboratoriesEPA-DHA 1000 mg100 mgper 1 Softgel Capsule(s)DSLD:261658
Pure EncapsulationsDHA Liquid1 Gram(s)per 1 mLDSLD:205211
Pure EncapsulationsEPA/DHA Vegetarian310 mgper 2 Caplique(R) Capsule(s)DSLD:182879
Pure EncapsulationsEPA/DHA Vegetarian310 mgper 2 Caplique(R) Capsule(s)DSLD:184456
Pure Label NutritionKrill Oil 1000 mg40 mgper 2 Capsule(s)DSLD:269590
Pure OneAlgae Oil350 mgper 1 Softgel(s)DSLD:43285
Pure OneAlgae Omega-3700 mgper 2 Vegetarian Softgel(s)DSLD:211607
Pure OneDHAlicious Organic Lemon & Green Tea Flavor720 mgper 1 mLDSLD:202540
Pure OneDHAlicious Organic Lemon Flavored180 mgper 0.5 mLDSLD:202543
Pure PrescriptionsPremium Omega-3DHA (Form: as Triglycerides) (Alt. Name: Docosahexaenoic Acid)480 mgper 2 Softgel(s)DSLD:228209
Puritan's PrideDHA 100 mg100 mgper 1 Softgel(s)DSLD:271068
Puritan's PrideExtra Strength DHA 500 mg500 mgper 1 Softgel(s)DSLD:286293
Puritan's PridePrenatal Multivitamin w/DHAAlgae · from DHA rich oil derived from a plant based algae200 mgper 2 Softgel(s)DSLD:286029
Purity LabsAntarctic Krill Oil80 mgper 2 Softgel(s)DSLD:313927
QualiaMindAlgae · DHA (Form: from Algae) (Alt. Name: Docosahexaenoic Acid)80 mgper 7 Vegetarian Capsule(s)DSLD:239658
QualiaMind Caffeine FreeAlgae80 mgper 1 Vegetarian Capsule(s)DSLD:314264
Quantum Nutrition LabsQuantum Plant DHAAlgal Oil200 mgper 1 Softgel(s)DSLD:302390
Quantum Nutrition LabsQuantum Plant DHAAlgal Oil200 mgper 1 Softgel(s)DSLD:329032
Remedys NutritionUltimate Omega-3 Fish Oil82 mgper 1 Vegetarian Capsule(s)DSLD:272190
Renew LifeSuper Critical Omega240 mgper 1 Softgel(s)DSLD:2345
Rexall SundownMarvel Heroes GummiesFish Oil · DHA (Form: from Fish Oil) (Alt. Name: Docosahexaenoic Acid)100 mcgper 2 Gummy(ies)DSLD:26206
Rite Aid PharmacyNatural Fish Oil 1000 mgDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3200 mgper 2 Softgel(s)DSLD:181533
Rite Aid PharmacyNatural Fish Oil 1000 mgDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3200 mgper 2 Softgel(s)DSLD:239751
Rite Aid PharmacyOmega 3-6-9 Lemon Natural FlavorDHA (Alt. Name: Docosahexaenoic Acid) Note: Omega-3120 mgper 3 Softgel Capsule(s)DSLD:239828
Ron Teeguarden NutraceuticalsDHA 100 mgMicroalgae Oil100 mgper 1 Vegetarian Softgel(s)DSLD:316670
RugbyOmega-3 Krill Oil17 mgper 1 Softgel(s)DSLD:201205
Salaam NutritionalsOmega 3 Fish Oil600 mgper 2 Softgel(s)DSLD:292292
Salaam NutritionalsPrenatal140 mgper 4 Gummy(ies)DSLD:247265
Salaam NutritionalsPrenatal DHA + Folate105 mgper 4 Gummy(ies)DSLD:292290
Science Natural SupplementsOmega-3X EPA 432 mg/DHA 288 mg288 mgper 1 Softgel(s)DSLD:276468
SeniorLife HealthOmega 3-6-9 Complete48 mgper 1 Softgel(s)DSLD:256552
SFHSO3 Super Omega 3 LemonDHA (Alt. Name: Docosahexaenoic Acid) Note: 1025-1075mg1,075 mgper 1 tspDSLD:16320
SFHSO3 SuperOmega3 LemonDHA (Alt. Name: Docosahexaenoic Acid) Note: 1025-1075mg1,075 mgper 1 tspDSLD:16322
ShakleeVegan Omega-3Algal400 mgper 2 Softgel(s)DSLD:318625
SimplySupplementsOmega 3 Fish Oil 1000 mg120 mgper 1 Capsule(s)DSLD:22011
SimplySupplementsOmegaMax220 mgper 1 Capsule(s)DSLD:22533
SmarterVitaminsOmega-3 Strawberry Flavored600 mgper 2 Softgel(s)DSLD:243878
SmartyPantsBaby Multi & DHAAlgae · Omega-350 mgper 1 mLDSLD:266165
SmartyPantsMen's 50+ FormulaAlgal Oil · omega-3 DHA100 mgper 1 Capsule(s)DSLD:306756
SmartyPantsMen's 50+ FormulaAlgal Oil · omega-3 DHA100 mgper 1 Capsule(s)DSLD:306757
SmartyPantsMen's FormulaAlgal Oil · omega-3 DHA100 mgper 1 Capsule(s)DSLD:306758
SmartyPantsMen's FormulaAlgal Oil · omega-3 DHA100 mgper 1 Capsule(s)DSLD:306759
SmartyPantsPrenatal FormulaAlgal Oil · omega-3 DHA100 mgper 1 Capsule(s)DSLD:306750
SmartyPantsPrenatal FormulaAlgal Oil · omega-3 DHA100 mgper 1 Capsule(s)DSLD:306751
SmartyPantsWomen's 50+ MultiAlgal Oil · omega-3 DHA100 mgper 1 Capsule(s)DSLD:306753
SmartyPantsWomen's FormulaAlgal Oil · omega-3 DHA100 mgper 1 Capsule(s)DSLD:306755
SolarayDHA 100 mg Plant SourcedAlgal Oil100 mgper 1 Vegan Softgel(s)DSLD:338304
SolgarNaturally Sourced Omega-3 Vegetarian DHA 200 mgDocosahexaenoic Acid (Alt. Name: DHA) Note: from200 mgper 1 Softgel(s)DSLD:77225
SomaLife InternationalOmega-3DHA Note: Min 20%240 mgper 1 Capsule(s)DSLD:33371
Source NaturalsAttentive DHA 100 mgAlgal Oil · Docosahexaenoic Acid (Form: from Algal Oil (Alt. Name: life'sDHA)) (Alt. Name: DHA)100 mgper 1 Softgel(s)DSLD:214030
Source NaturalsAttentive DHA 100 mgAlgal Oil · Docosahexaenoic Acid (Form: from Algal Oil (Alt. Name: life'sDHA)) (Alt. Name: DHA)100 mgper 1 Softgel(s)DSLD:273085
Source NaturalsComplete Essential Fatty AcidsDocosahexaenoic Acid (Alt. Name: DHA) Note: Omega-3192 mgper 3 Softgel(s)DSLD:214196
Source NaturalsComplete Essential Fatty AcidsDocosahexaenoic Acid (Alt. Name: DHA) Note: Omega-3192 mgper 3 Softgel(s)DSLD:214207
Source NaturalsNeuromins DHA 100 mgAlgal Oil · Docosahexaenoic Acid (Form: from Algal Oil (Alt. Name: life'sDHA)) (Alt. Name: DHA)200 mgper 1 Softgel(s)DSLD:211644
Source NaturalsNeuromins DHA 200 mgAlgal Oil · Docosahexaenoic Acid (Form: from Algal Oil) (Alt. Name: DHA, life'sDHA)600 mgper 3 Softgel(s)DSLD:213589
Source NaturalsNeuromins DHA 200 mgAlgal Oil · Docosahexaenoic Acid (Form: from Algal Oil) (Alt. Name: DHA, life'sDHA)600 mgper 3 Softgel(s)DSLD:213604
Source NaturalsNeuromins DHA 200 mgAlgal Oil · Docosahexaenoic Acid (Form: from Algal Oil) (Alt. Name: DHA, life'sDHA)600 mgper 3 Softgel(s)DSLD:272854
Source NaturalsOmega 3-6-9Docosahexaenoic Acid (Alt. Name: DHA) Note: omega-3192 mgper 3 Softgel(s)DSLD:273928
Source NaturalsOmega 3-6-9Omega-3192 mgper 3 Softgel(s)DSLD:275607
Source NaturalsOmegaEPA Fish Oil 120 mgper 1 Softgel(s)DSLD:275432
Source NaturalsVegan Omega-3s 300 mg360 mgper 1 Softgel(s)DSLD:273971
Source NaturalsVegan Omega-3s 300 mg360 mgper 1 Softgel(s)DSLD:273974
Source NaturalsVegan Omega-3s 300 mg360 mgper 1 Softgel(s)DSLD:78805
Source NaturalsVegan True Non-Fish Omega-3s 300 mg360 mgper 1 Softgel(s)DSLD:274005
Source NaturalsVegetarian DHA 200 mgAlgal Oil · Docosahexaenoic Acid (Form: from Algal Oil) (Alt. Name: life'sDHA)600 mgper 1 Vegetarian Softgel(s)DSLD:78941
Source OilAlgae Omega-32,000 mgper 2 mLDSLD:211605
Source OilAlgae Omega-3 Organic Lemon Flavor2,000 mgper 0.5 Teaspoon(s)DSLD:211612
SP Standard ProcessCalamari Omega-3 Liquid800 mgper 5 mLDSLD:256403
SP Standard ProcessCod Liver Oil300 mgper 3 Softgel(s)DSLD:256486
SP Standard ProcessCod Liver Oil300 mgper 3 Softgel(s)DSLD:340155
SP Standard ProcessGeneral Health Daily Fundamentals300 mgper 1 Pack(s)DSLD:292105
SP Standard ProcessTuna Omega-3 Chewable240 mgper 2 Softgel(s)DSLD:340291
Spring ValleyAdult Gummy Omega-3 Complex with EPA/DHA50 mgper 2 Gummie(s)DSLD:73430
Spring ValleyAlgal-900 DHA450 mgper 1 Softgel(s)DSLD:13039
Spring ValleyDHA 200 mgAlgal Docosahexaenoic Acid200 mgper 1 Softgel(s)DSLD:26458
SundownMarvel The Amazing Spider-Man CompleteFish Oil · DHA (Form: from Fish Oil) (Alt. Name: Docosahexaenoic Acid)50 mcgper 0.5 Tablet(s)DSLD:197373
Sundown NaturalsVitamin EssentialsAlgal · Docosahexaenoic Acid (Form: from DHA rich oil derived from a plant based algae Schizochytrium sp. Genus: Schizochytrium Species: sp.) (Alt. Name: DHA)100 mgper 1 Packet(s)DSLD:29566
SuntoryDHA & EPA Sesamin EX300 mgper 4 Softgel(s)DSLD:174978
SuperSmartSuper Omega 3 1500 mgFish Oil · in Triglyceride form345 mgper 1 Softgel(s)DSLD:315661
Supplement SpotEssential Prostate Packfish oil100 mgper 1 Packet(s)DSLD:264557
SwansonBrain Essentials30 mgper 1 Veggie Capsule(s)DSLD:308484
SynergyNorwegian Cod Liver Oil Lemon500 mgper 5 mLDSLD:277453
Systemic Formulas Bio NutrimentOMGA LQ236.6 mgper 2 mLDSLD:22120
The Honest Co.Baby DHA95 mgper 1 mLDSLD:206813
The Honest Co.DHA/Omega-3250 mgper 1 Softgel(s)DSLD:73709
The Vitamin ShoppeAdvanced Ocular SupportFish Oil · Docosahexaenoic Acid (Form: from Fish Oil) (Alt. Name: DHA)50 mgper 2 Veggie Capsule(s)DSLD:35605
The Vitamin ShoppeGinkgo Neuro-Mind 60 mg50 mgper 1 Tablet(s)DSLD:36283
The Vitamin ShoppeOmega 3 Fish Oil 800 EPA/500 DHA500 mgper 1 Teaspoon(s)DSLD:26980
The Vitamin ShoppePrenatal + DHA50 mgper 4 Tablet(s)DSLD:37603
Theralogix Nutritional ScienceTheraNatal Complete Softgel300 mgper 1 Softgel(s)DSLD:283003
Theralogix Nutritional ScienceTheraNatal One300 mgper 1 Softgel(s)DSLD:282955
ThorneSynaQuellAlgal Oil125 mgper 7.8 Gram(s)DSLD:337875
ThorneVeganPro Complex Chocolate FlavoredAlgal Oil200 mgper 52.3 Gram(s)DSLD:313925
TN Trusted NutrientsDHADHA (Alt. Name: Docosahexaenoic Acid) Note: from100 mgper 1 Softgel(s)DSLD:70305
Trigen LaboratoriesTaron-Prex Prenatal with DHAFish Oil · DHA (Alt. Name: Docosahexaenoic Acid) Note: from approximately 350 mg of Omegas derived from approximately 580 mg purified fish oil265 mgper 1 Softgel Capsule(s)DSLD:241456
Trigen LaboratoriesTL-SelectFish Oil325 mgper 1 Softgel Capsule(s)DSLD:264481
Trigen LaboratoriesZatean -Pn DHA300 mgper 1 Softgel Capsule(s)DSLD:264497
Trigen LaboratoriesZatean -Pn Plus300 mgper 1 Softgel Capsule(s)DSLD:264498
Trigen LaboratoriesZatean-Pn DHA300 mgper 1 Capsule(s)DSLD:12964
TruehopeOmegapower360 mgper 3 Softgel Capsule(s)DSLD:32361
TruHeightKids Brain Growth Orange FlavorAlgal Oil100 mgper 2 Gummy(ies)DSLD:322969
Vertical PharmaceuticalsOB Complete Chewable100 mgper 1 Chewable Tablet(s)DSLD:264181
VigorSourceAlaska Deep Sea Fish Oil King240 mgper 1 Softgel(s)DSLD:12936
Village VitalityKrill Oil37.5 mgper 1 Softgel(s)DSLD:310246
VinsicCompound Neuralgic AcidAlgal Oil80 mgper 2 Softgel(s)DSLD:335760
Virtus PharmaceuticalsVirt-PN DHAFish Oil · Docosahexaenoic Acid (Alt. Name: DHA) Note: from at least 330 mg purified fish oils.300 mgper 1 Softgel(s)DSLD:180546
Virtus PharmaceuticalsVirt-PN PlusFish Oil · Docosahexaenoic Acid (Alt. Name: DHA) Note: from at least 340 mg omega-3s from at least 390 purified fish oils.300 mgper 1 Softgel(s)DSLD:180537
VitabaseBrain Support100 mgper 2 Capsule(s)DSLD:7004
VitabaseComplete Essential Fatty Acids46 mgper 1 Softgel(s)DSLD:6864
VitabaseKrill Oil 500 mg52 mgper 1 Softgel(s)DSLD:6160
VitabaseMaxEPA Omega-3 1000 mg120 mgper 1 Softgel(s)DSLD:6906
VitabaseNeuromins DHA 100 mgMicroalgae Oil · DHA (Form: from microalgae oil) (Alt. Name: docosahexaenoic acid) Note: Neuromins(TM) is a highly-purified source of DHA from microalgae. It is produced under strict quality control conditions and is free of chemical pollutants and toxins.100 mgper 1 Softgel(s)DSLD:7176
VitaCeutical LabsCardio Support Softgels80 mgper 1 Softgel(s)DSLD:6276
VitaCeutical LabsEPA & DHA120 mgper 1 Softgel(s)DSLD:53841
VitaCeutical LabsEPA & DHA120 mgper 1 Softgel(s)DSLD:6307
VitaCeutical LabsKrill Oil37.5 mgper 1 Softgel(s)DSLD:53560
VitaCeutical LabsPrenatal With DHAAlgae · DHA (Form: from Algae)50 mgper 3 Tablet(s)DSLD:53993
Vital NutrientsUltra Omega CombinationDHA (Alt. Name: Docosahexaenoic Acid) Note: 160-176mg176 mgper 2 Softgel(s)DSLD:6322
Vital NutrientsUltra Pure Cod Liver Oil 1025 Lemon Flavored460 mgper 5 mLDSLD:305170
Vital NutrientsUltra Pure Fish Oil 350 Lemon Flavor240 mgper 1 Softgel(s)DSLD:223052
Vital NutrientsUltra Pure Fish Oil 350 Lemon Flavor240 mgper 2 Softgel(s)DSLD:305174
Vital NutrientsUltra Pure Omega CombinationDHA (Alt. Name: Docosahexaenoic Acid) Note: 160-176mg176 mgper 2 Softgel(s)DSLD:27523
vitaMedMDOne RxAlgal Oil200 mgper 1 Softgel(s)DSLD:264217
Vitamer LaboratoriesHigh Potency Liquid Omega-3440 mgper 1 tspDSLD:53242
Vitamer LaboratoriesHigh Potency Liquid Omega-3 Orange425 mgper 1 tspDSLD:53168
Vitamer LaboratoriesKrill Oil37.5 mgper 1 Softgel(s)DSLD:23274
Vitamer LaboratoriesKrill Oil37.5 mgper 1 Softgel(s)DSLD:67592
Vitamer LaboratoriesPrenatal Multi Once Daily CapsAlgae · DHA (Form: from Algae)15 mgper 1 Capsule(s)DSLD:68796
Vitamer LaboratoriesPrenatal With DHAAlgae · DHA (Form: from Algae) (Alt. Name: Docosahexaenoic Acid)50 mgper 1 Tablet(s)DSLD:69230
Vitamin WorldDHA 100 mg100 mgper 1 Softgel(s)DSLD:66291
Vitamin WorldNeuro-PS Gold Plus10 mgper 3 Softgel(s)DSLD:67655
Vitamin WorldPre & Post Natal DHA 100 mgAlgae · Docosahexaenoic Acid (Alt. Name: DHA) Note: from DHA rich oil derived from a plant based algae100 mgper 1 Softgel(s)DSLD:21071
Viva NaturalsLiquid Omega-3 Fish Oil Lemon SwirlDHA (Form: as TG) (Alt. Name: Docosahexaenoic Acid)510 mgper 5 mLDSLD:248115
Viva NaturalsTriple-Strength Omega-3 Fish OilDHA (Form: as TG) (Alt. Name: Docosahexaenoic Acid)480 mgper 2 Softgel(s)DSLD:247978
Viva NaturalsTriple-Strength Omega-3 Fish OilDHA (Form: as TG) (Alt. Name: Docosahexaenoic Acid)480 mgper 2 Softgel(s)DSLD:248141
Viva VitaminsFish Oil Omega-3120 mgper 1 Softgel(s)DSLD:1792
VQ Verified QualityOmega 3 Fish Oil 180 mg EPA/120 mg DHA Lemon FlavorDHA Note: 120-140mg140 mgper 1 Softgel(s)DSLD:33987
Well at WalgreensSoftgelSchizochytrium sp. oil200 mgper 1 Softgel(s)DSLD:274227
Well At WalgreensPrenatal Multi + DHAAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic acid)250 mgper 1 Softgel(s)DSLD:207376
Whole FoodsPrenatal EssentialsAlgae · DHA (Form: from Algae)25 mgper 3 Tablet(s)DSLD:26523
Wholesome StoryMale Fertility SupportAlgae100 mgper 3 Capsule(s)DSLD:335612
Wholly LiquidOmega Plus300 mgper 1 Softgel(s)DSLD:272113
Wholly LiquidOmega Plus300 mgper 1 Softgel(s)DSLD:321788
Women's Choice PharmaceuticalsDHA/EPA Capsule230 mgper 1 Capsule(s)DSLD:241428
Women's Choice PharmaceuticalsNestabs OneAlgal Oil225 mgper 1 Softgel(s)DSLD:279130
Womens Choice PharmaceuticalsOmega 3-DHA120 mgper 1 Softgel(s)DSLD:37269
Wonder LaboratoriesDHA 100 mgFish Oil100 mgper 1 Softgel(s)DSLD:260684
Wonder LaboratoriesDHA 100 mgFish Oil100 mgper 1 Softgel(s)DSLD:260924
Wonder LaboratoriesDHA 100 mgFish Oil100 mgper 1 Softgel(s)DSLD:315170
Wonder LaboratoriesDHA 100 mgFish Oil100 mgper 1 Softgel(s)DSLD:315671
WP Westminster PharmaceuticalsWesCap-PN DHA300 mgper 1 Softgel(s)DSLD:278685
WP Westminster PharmaceuticalsWestGel DHA200 mgper 1DSLD:264460
XYMOGENBrainSustain Creamy ChocolateAlgal Oil · life'sDHA DHA (Form: from Algal oil) (Alt. Name: Docosahexaenoic Acid)50 mgper 51 Gram(s)DSLD:240120
XYMOGENBrainSustain Vanilla DelightAlgal Oil · life'sDHA DHA (Form: from Algal oil) (Alt. Name: Docosahexaenoic Acid)50 mgper 48 Gram(s)DSLD:218511
XYMOGENDHA from AlgaeAlgal Oil · life'sDHA DHA (Form: from Algal oil) (Alt. Name: Docosahexaenoic Acid)200 mgper 1 Vegetarian Softgel(s)DSLD:218646
XYMOGENDr. Perlmutter's DHA From Algae For KidsAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)100 mgper 1 Vegetarian Softgel(s)DSLD:27847
XYMOGENMaX Liv DetoxAlgal Oil · DHA (Form: from Algal Oil) (Alt. Name: Docosahexaenoic Acid)5 mgper 2 Capsule(s)DSLD:49608
ZahlerOmega 3 Liquid820 mgper 1 tspDSLD:33312
ZahlerOmega 3 Liquid820 mgper 1 tspDSLD:33314

Label record: NIH Office of Dietary Supplements · CC0

Where it reaches

10 systems, 28 regions, 166 tissues, 255 transporter routes — routes, not measurements: transporters known to carry all-cis-docosa-4,7,10,13,16,19-hexaenoic acid are expressed there, and no source reports it arriving.

Loading the model…

Nervous

Endocrine

Respiratory

Cardiovascular

Digestive

Urinary

Reproductive

Blood and immune

Musculoskeletal

Skin and adipose

Papers screened

1,487 papers

Compound: all-cis-docosa-4,7,10,13,16,19-hexaenoic acid
Screened: 1,487
Admitted: 5
Discarded: 1,105
Not read: 377
Showing: 200 of 1,487

The whole record

Produced a finding5 papers

PMID:336712202026-10-11

and 4 more.

Read and discarded1,105 papers

PMID:12391014cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:12590139cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:12923200cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:13130128cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:14715958cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:15569878cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:15590152cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:15718470cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:15852374cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:16040805cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:16151530cited by PMID:19804838; not about the subject it would be filed under2026-10-12
PMID:16432513cited by PMID:19804838; not about the subject it would be filed under2026-10-12

and 1,093 more.

Not read yet377 papers

and 377 more.

Measured, not recorded

Compound: all-cis-docosa-4,7,10,13,16,19-hexaenoic acid
Endpoints measured: 633 endpoints
Recorded as a finding: No

Show what was measured

HDL-cholesterol (HDL-C)
increases, 0.07 mmol/L (95% CI: 0.05-0.10)
The pooled estimate for the change in TG concentration was -0.20 mmol/L (95% CI: -0.27 to -0.14), 0.23 mmol/L (95% CI: 0.16-0.30) for LDL-C, and 0.07 mmol/L (95% CI: 0.05-0.10) for HDL-C.
PMID:22113870 · one of two readings recorded this
LDL-cholesterol (LDL-C)
increases, 0.23 mmol/L (95% CI: 0.16-0.30)
The pooled estimate for the change in TG concentration was -0.20 mmol/L (95% CI: -0.27 to -0.14), 0.23 mmol/L (95% CI: 0.16-0.30) for LDL-C, and 0.07 mmol/L (95% CI: 0.05-0.10) for HDL-C.
PMID:22113870 · one of two readings recorded this
serum triglycerides (TG)
decreases, -0.20 mmol/L (95% CI: -0.27 to -0.14)
The pooled estimate for the change in TG concentration was -0.20 mmol/L (95% CI: -0.27 to -0.14), 0.23 mmol/L (95% CI: 0.16-0.30) for LDL-C, and 0.07 mmol/L (95% CI: 0.05-0.10) for HDL-C.
PMID:22113870 · one of two readings recorded this
brain DHA uptake / brain DHA levels
decreases, markedly reduced levels of DHA in brain of Mfsd2a-knockout mice
Lipidomic analysis indicates that Mfsd2a-deficient (Mfsd2a-knockout) mice show markedly reduced levels of DHA in brain accompanied by neuronal cell loss in hippocampus and cerebellum, as well as cognitive deficits and severe anxiety, and microcephaly.
PMID:24828044 · one of two readings recorded this
DHA levels in brain, lipidomic analysis
decreases
Lipidomic analysis indicates that Mfsd2a-deficient (Mfsd2a-knockout) mice show markedly reduced levels of DHA in brain accompanied by neuronal cell loss in hippocampus and cerebellum, as well as cognitive deficits and severe anxiety, and microcephaly.
PMID:24828044 · one of two readings recorded this
episodic memory, adults with mild memory complaints (MMC)
increases, Hedge's g z = 2.86 (p = 0.004), p = 0.004, n = 18
In the a priori meta-analysis model of adults with MMC, episodic memory significantly (P<.004) improved in response to DHA supplementation, alone or in combination with EPA; Table 2).
PMID:25786262 · one of two readings recorded this
episodic memory, pooled between-group (all subjects)
no effect, WGMD 0.08 (z=1.777, p=0.076); Hedge's g z=1.647 (p=0.10), p = 0.076, n = 62
The overall model and the analysis of episodic memory in response to DHA/EPA supplementation among adults with no cognitive complaints at baseline was not significant (Table 2).
PMID:25786262 · one of two readings recorded this
episodic, semantic and working memory, pooled weighted mean difference and Hedge's g across neuropsychological memory tests
no effect, overall between-group episodic memory model not significant (WGMD 0.08, z=1.777, p=0.076; Hedge's g z=1.647, p=0.10), p = 0.076, n = 62
Not recorded as a finding: the intervention held more than the compound
The overall model and the analysis of episodic memory in response to DHA/EPA supplementation among adults with no cognitive complaints at baseline was not significant (Table 2).
PMID:25786262 · one of two readings recorded this
semantic memory, pooled between-group
no effect, n = 15
No significant effects of DHA/EPA supplementation were found for any of the between group models analyzed (See Supporting Information— S3 Table).
PMID:25786262 · one of two readings recorded this
working memory, pooled between-group
no effect, n = 21
No significant effects of DHA/EPA supplementation were found for any of the between group models analyzed (See Supporting Information— S4 Table).
PMID:25786262 · one of two readings recorded this
Baseline diastolic blood pressure, 1 g/day group
no effect, p = 0.58
with a trend towards lower systolic (p = 0.07) but not diastolic (p = 0.58) blood pressure in the 1 g/day group
PMID:30297663 · one of two readings recorded this
Baseline fasting plasma triglyceride, whole cohort
no effect, p = 0.56
The average baseline fasting TG level of the study cohort was 1.23 ± 0.47 mmol/L (mean ± standard deviation (SD)), with no difference between dose groups (p = 0.56)
PMID:30297663 · one of two readings recorded this
Baseline plasma total cholesterol between groups
no effect, p = 0.98
There was no difference between groups in baseline plasma TC levels (p = 0.98)
PMID:30297663 · one of two readings recorded this
Baseline systolic blood pressure, 1 g/day group
no effect, p = 0.07
with a trend towards lower systolic (p = 0.07) but not diastolic (p = 0.58) blood pressure in the 1 g/day group
PMID:30297663 · one of two readings recorded this
BMI as predictor of baseline plasma triglyceride
increases, p = 0.03
BMI was a weak but significant predictor of baseline plasma TG levels (R2 = 0.09, p = 0.03)
PMID:30297663 · one of two readings recorded this
Change in proportion of HDL2a particles, predicted by change in LDL peak particle size
unclear, p = 0.003
HDL2a (R2 = 0.28, p = 0.003)
PMID:30297663 · one of two readings recorded this
Change in proportion of HDL2b particles, predicted by change in LDL peak particle size
unclear, p = 0.0008
the change in LDL peak particle size was a predictor of the change in the proportion of HDL2b (R2 = 0.34, p = 0.0008)
PMID:30297663 · one of two readings recorded this
Change in proportion of HDL2b particles, predicted by change in plasma TG
unclear, p = 0.04
The change in plasma TG levels was a predictor of the change in the proportion of HDL2b particles (R2 = 0.15, p = 0.04)
PMID:30297663 · one of two readings recorded this
Change in proportion of HDL3b particles, predicted by change in LDL peak particle size
unclear, p = 0.01
HDL3b (R2 = 0.20, p = 0.01)
PMID:30297663 · one of two readings recorded this
Diastolic blood pressure after supplementation, by n-3 LCPUFA dose
no effect, p = 0.91
After fish oil supplementation, both systolic (p = 0.16) and diastolic (p = 0.91) blood pressures were unaffected by n-3 LCPUFA dose
PMID:30297663 · one of two readings recorded this
fasting plasma triglycerides (autoanalyser enzymatic kit, fast over 10 h), pre-menopausal women, 8 weeks of HiDHA tuna oil at 0, 0.35, 0.7 or 1 g/day n-3 LCPUFA
decreases
Not recorded as a finding: the intervention held more than the compound
Following 8 weeks of supplementation with 1 g/day n-3 LCPUFA, plasma TG levels significantly lowered compared to placebo (Table 2).
PMID:30297663 · one of two readings recorded this
fasting plasma triglycerides (enzymatic autoanalyser, overnight fast over 10 h) after 8 weeks at 1 g/day n-3 LCPUFA as HiDHA tuna oil versus Sunola oil placebo; also total cholesterol, lipoprotein particle size, Omega-3 Index
decreases, n = 53
Not recorded as a finding: the intervention held more than the compound
Following 8 weeks of supplementation with 1 g/day n-3 LCPUFA, plasma TG levels significantly lowered compared to placebo (Table 2).
PMID:30297663 · one of two readings recorded this
HDL3-C, placebo vs 0.35 and 0.7 g/day groups
unclear
The significant difference between HDL3-C levels in the placebo group and the 0.35 and 0.7 g/day groups was driven by an unexplained increase in the placebo group rather than a reduction in the treatment groups
PMID:30297663 · one of two readings recorded this
IDL, LDL and HDL particle composition
no effect
IDL, LDL, and HDL particle compositions were unaffected by n-3 LCPUFA supplementation (Table 4)
PMID:30297663 · one of two readings recorded this
LDL particle size
no effect
small dense LDL3 particles present in very few subjects and no particle size change upon n-3 LCPUFA supplementation (Table 5)
PMID:30297663 · one of two readings recorded this
Omega-3 Index (erythrocyte EPA + DHA), increase
increases
resulting in a 15% increase in the Omega-3 Index (erythrocyte EPA + DHA as mol % of total fatty acids) after 0.35 g/day, and increases of 27% and 39% after 0.7 g/day and 1 g/day n-3 LCPUFA, respectively
PMID:30297663 · one of two readings recorded this
Omega-3 Index (erythrocyte EPA + DHA), increase
increases
resulting in a 15% increase in the Omega-3 Index (erythrocyte EPA + DHA as mol % of total fatty acids) after 0.35 g/day, and increases of 27% and 39% after 0.7 g/day and 1 g/day n-3 LCPUFA, respectively
PMID:30297663 · one of two readings recorded this
Omega-3 Index (erythrocyte EPA + DHA), increase
increases
resulting in a 15% increase in the Omega-3 Index (erythrocyte EPA + DHA as mol % of total fatty acids) after 0.35 g/day, and increases of 27% and 39% after 0.7 g/day and 1 g/day n-3 LCPUFA, respectively
PMID:30297663 · one of two readings recorded this
Plasma total cholesterol dose-response after supplementation
no effect, p = 0.64
no dose–response effect following n-3 LCPUFA supplementation (p = 0.64)
PMID:30297663 · one of two readings recorded this
Plasma triglyceride, change from baseline
decreases
This change amounted to a 23% reduction from baseline
PMID:30297663 · one of two readings recorded this
Plasma triglyceride dose-response, intention-to-treat
decreases, p = 0.04
In an intention-to-treat analysis, plasma TG levels lowered according to increasing dose (R2 = 0.09, p = 0.04)
PMID:30297663 · one of two readings recorded this
Plasma triglyceride dose-response, per-protocol
decreases, p = 0.003
The dose effect increased upon a per-protocol analysis (R2 = 0.16, p = 0.003)
PMID:30297663 · one of two readings recorded this
Post-intervention VLDL-TG, 1 g/day vs 0.35 g/day
decreases
Post-intervention VLDL-TG levels in the group supplemented with 1 g/day n-3 LCPUFA were significantly lower (32%) than the 0.35 g/day group
PMID:30297663 · one of two readings recorded this
Post-intervention VLDL-TG, 1 g/day vs placebo
no effect
they were not significantly lower than placebo due to the apparent VLDL-TG reduction in this group (Table 3)
PMID:30297663 · one of two readings recorded this
Proportion of HDL2b particles
increases
There was a very weak dose-dependent increase in the proportion of HDL2b particles but not in HDL2a or HDL3a (Table 5)
PMID:30297663 · one of two readings recorded this
Systolic blood pressure after supplementation, by n-3 LCPUFA dose
no effect, p = 0.16
After fish oil supplementation, both systolic (p = 0.16) and diastolic (p = 0.91) blood pressures were unaffected by n-3 LCPUFA dose
PMID:30297663 · one of two readings recorded this
Child age at measurement as predictor of diastolic blood pressure
unclear, p = 0.001
DBP: F = 7.39; P = .001
PMID:30794304 · one of two readings recorded this
Child age at measurement as predictor of systolic blood pressure
unclear, p = 0.001
child age, SBP: F = 7.385; P = .001
PMID:30794304 · one of two readings recorded this
childhood systolic and diastolic blood pressure at 4-6 years, mixed models; mothers given 600 mg/day DHA vs placebo in pregnancy, outcome in children; finding reported only in children who were overweight or obese (treatment by weight-status interaction)
decreases, SBP 104.28 vs 100.34 mm Hg; DBP 64.7 vs 59.76 mm Hg (placebo vs DHA, overweight or obese children)
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
Children who were overweight or obese whose mothers received placebo during pregnancy had higher SBP and DBP compared with children who were overweight or obese whose mothers received DHA (mean [SE] SBP, 104.28 [1.37] mm Hg vs 100.34 [1.02] mm Hg; DBP, 64.7 [1.23] mm Hg vs 59.76 [0.91] mm Hg).
PMID:30794304 · one of two readings recorded this
childhood systolic and diastolic blood pressure at 4 to 6 years in offspring of mothers given 600 mg/d DHA in pregnancy; reported only by child weight-status stratum (overweight or obese versus not); abstract only
decreases, SBP 100.34 vs 104.28 mm Hg; DBP 59.76 vs 64.7 mm Hg in overweight or obese children, DHA versus placebo, n = 171
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
Children who were overweight or obese whose mothers received placebo during pregnancy had higher SBP and DBP compared with children who were overweight or obese whose mothers received DHA (mean [SE] SBP, 104.28 [1.37] mm Hg vs 100.34 [1.02] mm Hg; DBP, 64.7 [1.23] mm Hg vs 59.76 [0.91] mm Hg).
PMID:30794304 · one of two readings recorded this
Diastolic blood pressure in children aged 4 to 6 years
decreases
DBP, 64.7 [1.23] mm Hg vs 59.76 [0.91] mm Hg
PMID:30794304 · one of two readings recorded this
Maternal prepregnancy BMI as predictor of child diastolic blood pressure
increases, p = 0.01
DBP: r = 0.216; P = .01
PMID:30794304 · one of two readings recorded this
Maternal prepregnancy BMI as predictor of child systolic blood pressure
increases, p = 0.001
prepregnancy BMI, SBP: r = 0.284; P = .001
PMID:30794304 · one of two readings recorded this
Systolic and diastolic blood pressure, children not overweight or obese vs overweight or obese children of DHA mothers
no effect
No differences in the SBP and DBP were found between children who were overweight or obese whose mothers received DHA and children who were not overweight or obese
PMID:30794304 · one of two readings recorded this
Systolic blood pressure in children aged 4 to 6 years
decreases
mean [SE] SBP, 104.28 [1.37] mm Hg vs 100.34 [1.02] mm Hg
PMID:30794304 · one of two readings recorded this
Inflammatory markers in maternal and infant plasma, correlation with RBC DHA
decreases
Decreases in inflammation were observed in both maternal and infant plasma and correlated with red blood cell (RBC) DHA levels
PMID:31058771 · one of two readings recorded this
inflammatory markers in maternal and infant plasma; mothers of extremely preterm infants assigned 200 or 1000 mg/day DHA, so both arms were exposed; abstract only
decreases
Not recorded as a finding: the comparison was against another active treatment
Decreases in inflammation were observed in both maternal and infant plasma and correlated with red blood cell (RBC) DHA levels.
PMID:31058771 · one of two readings recorded this
Caregiver-reported child sleep, change over 180 days, entire cohort
no effect
Differences in change between the DHA+AA and placebo groups after 180 days of supplementation were not statistically significant for the entire cohort
PMID:31538590 · one of two readings recorded this
caregiver-reported toddler sleep (nocturnal and total sleep, sleep problems), Brief Infant Sleep Questionnaire, 180 days of supplementation in children born preterm
no effect, difference in change between DHA+AA and placebo not statistically significant for the entire cohort
Not recorded as a finding: the intervention held more than the compound
Differences in change between the DHA+AA and placebo groups after 180 days of supplementation were not statistically significant for the entire cohort.
PMID:31538590 · one of two readings recorded this
caregiver-reported toddler sleep (nocturnal sleep, total sleep, sleep problems) on the Brief Infant Sleep Questionnaire, change over 180 days; abstract only
no effect
Not recorded as a finding: the intervention held more than the compound
Differences in change between the DHA+AA and placebo groups after 180 days of supplementation were not statistically significant for the entire cohort.
PMID:31538590 · one of two readings recorded this
Nocturnal sleep change
increases, p = 0.006
difference in nocturnal sleep change = 1.07, effect size = 0.65, P = .006
PMID:31538590 · one of two readings recorded this
Nocturnal sleep change
increases, p = 0.04
difference in nocturnal sleep change = 0.44, effect size = 0.26, P = .04
PMID:31538590 · one of two readings recorded this
Sleep problems
decreases
sleep problems odds ratio = 0.36, 95% confidence interval = 0.15, 0.82
PMID:31538590 · one of two readings recorded this
Total sleep change
increases, p = 0.04
difference in total sleep change = 1.10, effect size = 0.50, P = .04
PMID:31538590 · one of two readings recorded this
13C-DHA accumulation in red cell phosphatidylcholine
no effect
No significant differences were found for these kinetics for both sources.
PMID:31963708 · one of two readings recorded this
13C-DHA accumulation in red cell phosphatidylethanolamine
increases
When studying the accumulation of 13C-DHA into PE, it tended to plateauing at 144 h from 13C-DHA-TAG whereas it sharply increased at this latter time from 13C-AceDoPC, with around twice as much of 13C-DHA from AceDoPC.
PMID:31963708 · one of two readings recorded this
13C-DHA enrichment in plasma phospholipids after the peak
increases
After peaking, the 13C enrichment in DHA decreased at 72 h from both sources but remained significantly different.
PMID:31963708 · one of two readings recorded this
13C-DHA enrichment in plasma phospholipids and red-cell PC and PE after a single 50 mg 13C-DHA dose as 13C-AceDoPC versus 13C-DHA triacylglycerol, GC-C-IRMS; three men, crossover
peak 5386 pmol/mL from AceDoPC versus 3247 pmol/mL from TAG-DHA, n = 3
Not recorded as a finding: the comparison was against another active treatment
However, the 13 C-DHA peak was 2-fold higher from AceDoPC (5386 pmol/mL) compared to TAG-DHA (3247 pmol/mL).
PMID:31963708 · one of two readings recorded this
13C-DHA enrichment in plasma phospholipids and red cell phosphatidylcholine/ethanolamine, GC-C-IRMS, after 50 mg 13C-DHA as AceDoPC versus as triacylglycerol, crossover in three men
peak 5386 vs 3247 pmol/mL (AceDoPC vs TAG-DHA), n = 3
Not recorded as a finding: the comparison was against another active treatment
However, the 13 C-DHA peak was 2-fold higher from AceDoPC (5386 pmol/mL) compared to TAG-DHA (3247 pmol/mL).
PMID:31963708 · one of two readings recorded this
Peak 13C-DHA in plasma phospholipids
increases
However, the 13 C-DHA peak was 2-fold higher from AceDoPC (5386 pmol/mL) compared to TAG-DHA (3247 pmol/mL)
PMID:31963708 · one of two readings recorded this
bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age
The meta-analysis of these studies showed that DHA supplementation did not decrease the risk of BPD at 36 weeks of postmenstrual age among preterm infants (low certainty of evidence).
PMID:32456494 · one of two readings recorded this
Bronchopulmonary dysplasia among surviving infants, absolute difference
increases, p = 0.01
Bronchopulmonary dysplasia occurred in 41.7% of surviving infants in the DHA group vs 31.4% in the placebo group (absolute difference, 11.5% [95% CI, 2.3% to 23.2%]; relative risk, 1.36 [95% CI, 1.07 to 1.73], P = .01)
PMID:32662862 · one of two readings recorded this
Bronchopulmonary dysplasia among surviving infants
increases, p = 0.01
Bronchopulmonary dysplasia occurred in 41.7% of surviving infants in the DHA group vs 31.4% in the placebo group (absolute difference, 11.5% [95% CI, 2.3% to 23.2%]; relative risk, 1.36 [95% CI, 1.07 to 1.73], P = .01)
PMID:32662862 · one of two readings recorded this
Bronchopulmonary dysplasia-free survival at 36 weeks' postmenstrual age, absolute difference
no effect, p = 0.18
147 of 268 infants (54.9%) in the DHA group vs 157 of 255 infants (61.6%) in the placebo group survived without bronchopulmonary dysplasia (absolute difference, -5.0% [95% CI, -11.6% to 2.6%]; relative risk, 0.91 [95% CI, 0.80 to 1.04], P = .18)
PMID:32662862 · one of two readings recorded this
Bronchopulmonary dysplasia-free survival at 36 weeks' postmenstrual age
no effect, p = 0.18
147 of 268 infants (54.9%) in the DHA group vs 157 of 255 infants (61.6%) in the placebo group survived without bronchopulmonary dysplasia (absolute difference, -5.0% [95% CI, -11.6% to 2.6%]; relative risk, 0.91 [95% CI, 0.80 to 1.04], P = .18)
PMID:32662862 · one of two readings recorded this
bronchopulmonary dysplasia-free survival in infants at 36 weeks' postmenstrual age (primary outcome); mothers dosed 1.2 g/d DHA, outcome measured in their breastfed preterm infants; also mortality and bronchopulmonary dysplasia in survivors, abstract only
RR 0.91 (95% CI 0.80 to 1.04), p = 0.18, n = 523
Not recorded as a finding: this platform holds no node for the endpoint
Overall, 147 of 268 infants (54.9%) in the DHA group vs 157 of 255 infants (61.6%) in the placebo group survived without bronchopulmonary dysplasia (absolute difference, -5.0% [95% CI, -11.6% to 2.6%]; relative risk, 0.91 [95% CI, 0.80 to 1.04], P = .18).
PMID:32662862 · one of two readings recorded this
bronchopulmonary dysplasia in surviving infants at 36 weeks' postmenstrual age (and BPD-free survival, mortality), after maternal oral DHA 1.2 g/d vs placebo capsules; mothers dosed, outcome in preterm infants
BPD 41.7% vs 31.4% of survivors, RR 1.36 (95% CI 1.07 to 1.73), p = 0.01
Not recorded as a finding: the paper never states the instrument the node requires
Bronchopulmonary dysplasia occurred in 41.7% of surviving infants in the DHA group vs 31.4% in the placebo group (absolute difference, 11.5% [95% CI, 2.3% to 23.2%]; relative risk, 1.36 [95% CI, 1.07 to 1.73], P = .01).
PMID:32662862 · one of two readings recorded this
Mortality, absolute difference
no effect, p = 0.12
Mortality occurred in 6.0% of infants in the DHA group vs 10.2% of infants in the placebo group (absolute difference, -3.9% [95% CI, -6.8% to 1.4%]; relative risk, 0.61 [95% CI, 0.33 to 1.13], P = .12)
PMID:32662862 · one of two readings recorded this
Mortality
no effect, p = 0.12
Mortality occurred in 6.0% of infants in the DHA group vs 10.2% of infants in the placebo group (absolute difference, -3.9% [95% CI, -6.8% to 1.4%]; relative risk, 0.61 [95% CI, 0.33 to 1.13], P = .12)
PMID:32662862 · one of two readings recorded this
Prespecified secondary outcomes (22)
no effect
Of 22 prespecified secondary outcomes, 19 were not significantly different
PMID:32662862 · one of two readings recorded this
Adherence by pill count
no effect
Mean adherence by pill count in the overall sample was 80.4% (placebo mean (SD)=79.8 (21.8); DHA mean (SD)=80.9 (17.3))
PMID:32690472 · one of two readings recorded this
Association of change in plasma DHA with change in CSF DHA
increases, p = 0.001
Increasing plasma DHA was associated with an increase in CSF DHA (R = 0.91, p<0.001; Supp Figure 1a)
PMID:32690472 · one of two readings recorded this
Baseline age
no effect, p = 0.46
Age in years, median (min, max) | 69 (58, 79) | 68.5 (58, 90) | 0.46
PMID:32690472 · one of two readings recorded this
Baseline BMI
no effect, p = 0.13
BMI (kg/m2), median (IQR) | 32.0 (7.3) | 27.8 (5.8) | 0.13
PMID:32690472 · one of two readings recorded this
Baseline correlation of CSF DHA with CSF Aβ42
increases, p = 0.0033
higher CSF DHA levels were significantly correlated with higher CSF Aβ42 (r = 0.54; p = 0.0033)
PMID:32690472 · one of two readings recorded this
Baseline HgbA1c
no effect, p = 0.66
HgbA1c (%), median (IQR) | 5.7 (0.2) | 5.8 (0.6) | 0.66
PMID:32690472 · one of two readings recorded this
Baseline male participants
no effect, p = 0.37
Males, n (%) | 4 (27%) | 2 (11%) | 0.37
PMID:32690472 · one of two readings recorded this
Baseline MoCA
no effect, p = 0.62
MoCA, median (min, max) b | 27 (22, 30) | 28 (19, 30) | 0.62
PMID:32690472 · one of two readings recorded this
change in cerebrospinal fluid DHA concentration (primary), CSF fatty acids by GC-MS, 6 months of DHA 2152 mg/day vs corn/soy oil placebo, vitamin B complex in both arms
increases, mean difference 0.08 (95% CI 0.05, 0.10) ug/ml, n = 26
Not recorded as a finding: this platform holds no node for the endpoint
After six months of DHA supplementation, there was a significant increase in CSF DHA in the DHA supplement arm (n = 13) compared with placebo (n = 13) (mean difference (95% CI): 0.08 (0.05, 0.10) µg/ml; p<0.0001; Fig. 2a).
PMID:32690472 · one of two readings recorded this
Change in Craft Stories delayed recall
no effect, p = 0.52
Craft delayed recall | 0.4 (2.8) | 1.1 (2.8) | 0.7 (−1.5, 2.8) | 0.52
PMID:32690472 · one of two readings recorded this
Change in Craft Stories immediate recall
no effect, p = 0.23
Craft immediate recall | 1.7 (3.1) | 0.3 (3.2) | −1.4 (−3.9, 1.0) | 0.23
PMID:32690472 · one of two readings recorded this
Change in CSF arachidonic acid
no effect, p = 0.35
Levels of CSF AA did not differ after DHA treatment (−0.02 (−0.07, 0.02) µg/ml, p = 0.35)
PMID:32690472 · one of two readings recorded this
Change in CSF DHA/AA ratio
increases, p = 0.0001
CSF DHA/AA was increased among those taking DHA supplements compared with those taking placebo (0.27 (0.20, 0.34), p<0.0001)
PMID:32690472 · one of two readings recorded this
Change in CSF DHA
increases, p = 0.0001
there was a significant increase in CSF DHA in the DHA supplement arm (n = 13) compared with placebo (n = 13) (mean difference (95% CI): 0.08 (0.05, 0.10) µg/ml; p<0.0001; Fig. 2a)
PMID:32690472 · one of two readings recorded this
Change in CSF DHA
unclear, p = 0.08
There was a trend for a greater increase in CSF DHA in APOE4 non-carriers compared to carriers (0.02 (−0.003, 0.04), p = 0.08, Cohen's effect size d = 0.41)
PMID:32690472 · one of two readings recorded this
Change in CSF EPA/AA ratio
increases, p = 0.0001
There was an increase in CSF EPA/AA among those taking DHA supplements versus placebo (0.03 (0.02, 0.04), p<0.0001)
PMID:32690472 · one of two readings recorded this
Change in CSF EPA/AA ratio
increases, p = 0.02
and was greater among non-carriers compared to APOE4 carriers (0.01 (0.002, 0.03), p = 0.02)
PMID:32690472 · one of two readings recorded this
Change in CSF EPA
increases, p = 0.0001
CSF EPA levels were increased after DHA supplementation (0.008 (0.004, 0.01) µg/ml; p <0.0001; Fig. 2b)
PMID:32690472 · one of two readings recorded this
Change in CSF EPA
increases, p = 0.001
Change in CSF EPA levels in both groups was significantly greater in APOE4 non-carriers compared to carriers (0.006 (0.003, 0.009) µg/ml; p = 0.001)
PMID:32690472 · one of two readings recorded this
Change in CVLT delayed recall
no effect, p = 0.53
CVLT delayed recall | 1.3 (2.6) | 1.9 (2.6) | 0.6 (−1.4, 2.6) | 0.53
PMID:32690472 · one of two readings recorded this
Change in CVLT Trial 5 (ranked)
no effect, p = 0.09
CVLT Trial 5 (ranked) | 9.9 (7.1) | 14.6 (7.2) | 4.7 (−0.8, 10.2) | 0.09
PMID:32690472 · one of two readings recorded this
Change in CVLT Trial 5
increases, p = 0.03
CVLT Trial 5 | −0.8 (2.1) | 1.1 (2.2) | 1.9 (0.2, 3.5) | 0.03
PMID:32690472 · one of two readings recorded this
Change in entorhinal cortex measure, Cohen's d
no effect
Cohen's effect size d of the hippocampal and entorhinal volume changes after treatment were 0.24 and 0.54 respectively
PMID:32690472 · one of two readings recorded this
Change in entorhinal cortex thickness
no effect, p = 0.13
no significant differences in the change of hippocampal volume (−0.002 (−0.009, 0.005), p = 0.56) or entorhinal cortex thickness (−0.11 (−0.25, 0.03), p = 0.13) between DHA and placebo treatment arms
PMID:32690472 · one of two readings recorded this
Change in hippocampal volume, Cohen's d
no effect
Cohen's effect size d of the hippocampal and entorhinal volume changes after treatment were 0.24 and 0.54 respectively
PMID:32690472 · one of two readings recorded this
Change in hippocampal volume
no effect, p = 0.56
no significant differences in the change of hippocampal volume (−0.002 (−0.009, 0.005), p = 0.56) or entorhinal cortex thickness (−0.11 (−0.25, 0.03), p = 0.13) between DHA and placebo treatment arms
PMID:32690472 · one of two readings recorded this
Change in MoCA
no effect, p = 0.4
MoCA | 0.3 (1.6) | −0.2 (1.6) | −0.5 (−1.7, 0.7) | 0.40
PMID:32690472 · one of two readings recorded this
Change in plasma arachidonic acid
decreases, p = 0.005
Plasma AA levels were significantly lower after DHA supplementation (−45.5 (−75.4, −15.6) µg/ml, p = 0.005)
PMID:32690472 · one of two readings recorded this
Change in plasma arachidonic acid
decreases, p = 0.05
This difference in change was significant among APOE4 non-carriers (−57.7 (−115.1, −0.4) µg/ml, p<0.05)
PMID:32690472 · one of two readings recorded this
Change in plasma DHA/AA ratio
increases, p = 0.0001
change in plasma DHA/AA ratio (0.63 (0.48, 0.78), p<0.0001), and plasma EPA/AA ratio (0.09 (0.03, 0.15), p = 0.004) differed by treatment group
PMID:32690472 · one of two readings recorded this
Change in plasma DHA
increases, p = 0.0001
Plasma DHA levels after DHA supplementation was increased compared with placebo (106.4 (87.8, 125.1) µg/ml, p<0.0001; Fig. 2c)
PMID:32690472 · one of two readings recorded this
Change in plasma DHA
no effect, p = 0.12
DHA and EPA plasma levels did not significantly differ between APOE4 carriers and non-carriers (DHA: 14.7 (−4.2, 33.7) µg/ml, p = 0.12; EPA: 4.4 (−3.4, 12.3) µg/ml, p = 0.25; Fig. 2B and D)
PMID:32690472 · one of two readings recorded this
Change in plasma EPA/AA ratio
increases, p = 0.004
change in plasma DHA/AA ratio (0.63 (0.48, 0.78), p<0.0001), and plasma EPA/AA ratio (0.09 (0.03, 0.15), p = 0.004) differed by treatment group
PMID:32690472 · one of two readings recorded this
Change in plasma EPA
increases, p = 0.002
EPA plasma levels were also increased with DHA supplementation (13.8 (5.8, 21.7) µg/ml, p = 0.002; Fig. 2d)
PMID:32690472 · one of two readings recorded this
Change in plasma EPA
no effect, p = 0.25
DHA and EPA plasma levels did not significantly differ between APOE4 carriers and non-carriers (DHA: 14.7 (−4.2, 33.7) µg/ml, p = 0.12; EPA: 4.4 (−3.4, 12.3) µg/ml, p = 0.25; Fig. 2B and D)
PMID:32690472 · one of two readings recorded this
Change in Trail Making Test A
no effect, p = 0.8
Trails A | −2.8 (10.2) | −3.8 (10.3) | −1.0 (−8.8, 6.9) | 0.80
PMID:32690472 · one of two readings recorded this
Change in Trail Making Test B
no effect, p = 0.74
Trails B b | −1.5 (40.0) | 3.5 (40.2) | 5.0 (−26.3, 36.3) | 0.74
PMID:32690472 · one of two readings recorded this
CSF DHA concentration change over 6 months, fatty acid methyl esters by GC-MS (primary outcome); CSF and plasma EPA also measured
increases, mean difference 0.08 (95% CI 0.05, 0.10) µg/ml, n = 26
Not recorded as a finding: this platform holds no node for the endpoint
After six months of DHA supplementation, there was a significant increase in CSF DHA in the DHA supplement arm (n = 13) compared with placebo (n = 13) (mean difference (95% CI): 0.08 (0.05, 0.10) µg/ml; p<0.0001; Fig. 2a).
PMID:32690472 · one of two readings recorded this
Percentage increase in CSF DHA
increases
participants in the DHA treatment arm exhibited a 200% increase in plasma DHA, but only a 28% increase in CSF DHA
PMID:32690472 · one of two readings recorded this
Percentage increase in plasma DHA
increases
participants in the DHA treatment arm exhibited a 200% increase in plasma DHA, but only a 28% increase in CSF DHA
PMID:32690472 · one of two readings recorded this
Treatment by APOE genotype interaction on change in CSF EPA
no effect, p = 0.54
Interaction of APOE genotype and treatment on the change in CSF EPA level was not significant (p = 0.54)
PMID:32690472 · one of two readings recorded this
Treatment by APOE genotype interaction on CSF arachidonic acid
no effect, p = 0.32
there was no interaction between treatment and APOE genotype on levels of CSF AA (p = 0.32)
PMID:32690472 · one of two readings recorded this
Treatment by APOE genotype interaction on plasma arachidonic acid
no effect, p = 0.4
The interaction between APOE genotype and treatment arm on plasma AA was not significant (p = 0.40)
PMID:32690472 · one of two readings recorded this
Treatment by APOE group interaction on change in CSF DHA
no effect, p = 0.61
the interaction between the treatment group and APOE group on the change of CSF DHA was not significant (p = 0.61; Fig. 2a)
PMID:32690472 · one of two readings recorded this
Calcidiol (25-hydroxyvitamin D), change
increases, p = 0.0122
calcidiol (estimated difference 3.96 (95% CI 0.88, 7.04) μg/L; p = 0.0122)
PMID:32823606 · one of two readings recorded this
Change in maternal RBC DHA (wt% TFA), Visit 1 to Visit 4
increases, p = 0.0001, n = 141
the mean change from Visit 1 to Visit 4 was significantly greater in the MMS group compared with the control group, with an estimated treatment difference of 0.96 (95% CI 0.61, 1.31) (p < 0.0001)
PMID:32823606 · one of two readings recorded this
Delivery complications
no effect
a higher proportion of subjects in the control group compared with the MMS group experienced delivery complications (16 (23.2%) vs. eight (12.9%) subjects, respectively)
PMID:32823606 · one of two readings recorded this
Induced labor
no effect
or had an induced labor (13 (18.8%) vs. nine (14.5%) subjects)
PMID:32823606 · one of two readings recorded this
Infant bone density within 10 days after delivery
decreases, p = 0.0486
bone density in m2 (borderline significantly greater in the control group, p = 0.0486)
PMID:32823606 · one of two readings recorded this
Infant subscapular skinfold thickness at delivery
increases, p = 0.0292
subscapular skinfold thickness (thicker in the MMS group, p = 0.0292)
PMID:32823606 · one of two readings recorded this
Maternal RBC DHA/TFA ratio, change
increases, p = 0.0001
maternal RBC DHA/TFA ratio (estimated difference 0.01 (95% CI 0.006, 0.013); p < 0.0001)
PMID:32823606 · one of two readings recorded this
Maternal RBC DHA, women at lower ranges, change vs Visit 1
increases
compared to those in the control group (increase of 0.2% at Visit 3 and 0.5% at Visit 4 vs. Visit 1)
PMID:32823606 · one of two readings recorded this
Maternal RBC DHA, women at lower ranges, change vs Visit 1
increases
compared to those in the control group (increase of 0.2% at Visit 3 and 0.5% at Visit 4 vs. Visit 1)
PMID:32823606 · one of two readings recorded this
Maternal RBC DHA, women at lower ranges, change vs Visit 1
increases
RBC DHA levels in women at the lower ranges increased by a greater extent in the MMS group (1.1% at Visit 3 and 1.6% at Visit 4 vs. Visit 1)
PMID:32823606 · one of two readings recorded this
Maternal RBC DHA, women at lower ranges, change vs Visit 1
increases
RBC DHA levels in women at the lower ranges increased by a greater extent in the MMS group (1.1% at Visit 3 and 1.6% at Visit 4 vs. Visit 1)
PMID:32823606 · one of two readings recorded this
maternal red blood cell omega-3 index (EPA plus DHA, % of RBC fatty acids, gas chromatography) and RBC DHA wt% of total fatty acids, pregnant women, supplement from gestational week 13-15 to delivery
increases, omega-3 index estimated difference 1.00 (95% CI 0.64, 1.37)
Not recorded as a finding: the intervention held more than the compound
Significant differences were observed in favor of MMS for maternal RBC DHA/TFA ratio (estimated difference 0.01 (95% CI 0.006, 0.013); p < 0.0001), omega-3 index (estimated difference 1.00 (95% CI 0.64, 1.37); p < 0.0001), and calcidiol (estimated difference 3.96 (95% CI 0.88, 7.04) μg/L; p = 0.0122) (and Table 2).
PMID:32823606 · one of two readings recorded this
maternal red blood cell omega-3 index (EPA plus DHA, % of RBC fatty acids, gas chromatography), plus RBC DHA wt% (primary), DHA/TFA ratio and calcidiol
increases, omega-3 index estimated difference 1.00 (95% CI 0.64, 1.37)
Not recorded as a finding: the intervention held more than the compound
Significant differences were observed in favor of MMS for maternal RBC DHA/TFA ratio (estimated difference 0.01 (95% CI 0.006, 0.013); p < 0.0001), omega-3 index (estimated difference 1.00 (95% CI 0.64, 1.37); p < 0.0001), and calcidiol (estimated difference 3.96 (95% CI 0.88, 7.04) μg/L; p = 0.0122) (and Table 2).
PMID:32823606 · one of two readings recorded this
Omega-3 index (RBC EPA + DHA), change
increases, p = 0.0001
omega-3 index (estimated difference 1.00 (95% CI 0.64, 1.37); p < 0.0001)
PMID:32823606 · one of two readings recorded this
Other infant anthropometric variables at delivery
no effect
infant variables were comparable between groups, with no statistically significant differences
PMID:32823606 · one of two readings recorded this
Other secondary maternal endpoints (RBC TFA, RBC EPA, GSH/GSSG ratio, ROMs, 8-isoprostane)
no effect
were comparable between groups, albeit slightly higher in the MMS group, with no significant differences
PMID:32823606 · one of two readings recorded this
Age at start of complementary feeding
no effect
The age at which complementary feeding started was similar across groups (DHA vs. Placebo, mean ± SD: 5.4 ± 0.67 vs. 5.3 ± 0.83 months)
PMID:33023067 · one of two readings recorded this
Compliance with supplement
no effect
mean ± SD compliance did not differ by group (DHA: 93.0 ± 10.1; Placebo: 92.7 ± 10.7)
PMID:33023067 · one of two readings recorded this
infant development quotient at 12 months, Developmental Assessment Scale for Indian Infants (DASII, Indian modification of Bayley Scales); mothers dosed 400 mg/d algal DHA vs placebo, outcome in offspring
DQ 96.6 vs 97.1; mean difference (placebo minus DHA) 0.46 (95% CI -1.23, 2.14), p = 0.6
Not recorded as a finding: this platform holds no node for the endpoint
The DQ score (mean ± SD) at 12 months for the DHA and placebo groups was 96.6 ± 12.2 and 97.1 ± 13.0, respectively, and the mean difference (placebo minus DHA) was 0.46 (95% CI: −1.23, 2.14; p = 0.60).
PMID:33023067 · one of two readings recorded this
infant development quotient at 12 months, Developmental Assessment Scale for Indian Infants (DASII); mothers dosed 400 mg/d algal DHA in pregnancy and lactation, outcome measured in offspring
mean difference (placebo minus DHA) 0.46 (95% CI -1.23, 2.14), p = 0.6, n = 863
Not recorded as a finding: this platform holds no node for the endpoint
The DQ score (mean ± SD) at 12 months for the DHA and placebo groups was 96.6 ± 12.2 and 97.1 ± 13.0, respectively, and the mean difference (placebo minus DHA) was 0.46 (95% CI: −1.23, 2.14; p = 0.60).
PMID:33023067 · one of two readings recorded this
Infant development quotient at 12 months, interaction by child gender
modulates, p = 0.013
The p-value for interaction was significant for gender of the child (p = 0.013)
PMID:33023067 · one of two readings recorded this
Infant development quotient at 12 months, other prespecified subgroups
no effect
The mean DQ score did not differ significantly across mother’s age group, BMI, gravida, gestation age at delivery, compliance rate, duration of supplementation, physical activity
PMID:33023067 · one of two readings recorded this
Infant development quotient at 12 months, per protocol analysis
no effect
The per protocol analysis also showed no difference in 12-month DQ scores between the two groups (Table S3)
PMID:33023067 · one of two readings recorded this
Infant development quotient (DASII) at 12 months, female children
decreases
However, the mean DQ score for female child was higher in placebo as compared to DHA [mean difference (placebo− DHA) (95% CI): 2.74 (0.40, 5.09)]
PMID:33023067 · one of two readings recorded this
Infant development quotient (DASII) at 12 months
no effect, p = 0.6, n = 863
The DQ score (mean ± SD) at 12 months for the DHA and placebo groups was 96.6 ± 12.2 and 97.1 ± 13.0, respectively, and the mean difference (placebo minus DHA) was 0.46 (95% CI: −1.23, 2.14; p = 0.60)
PMID:33023067 · one of two readings recorded this
Infant motor and mental scores at 12 months
no effect
The motor and mental scores also did not differ significantly across the groups at 12 months (Table 5)
PMID:33023067 · one of two readings recorded this
Initiation of breastfeeding within 1 h
no effect
Initiation of breastfeeding in 1 h did not differ across groups (DHA vs. Placebo: 79.9% vs. 81.7%)
PMID:33023067 · one of two readings recorded this
Live births proportion
no effect
The proportion of live births was similar across both the groups (DHA vs. Placebo: 94.1% vs. 94.3%)
PMID:33023067 · one of two readings recorded this
Maternal RBC DHA change over intervention, DHA group
increases, p = 0.001
in the DHA group, concentrations increased by 1.04 (0.86, 1.23) mol % of fatty acid, paired t-test, p < 0.001
PMID:33023067 · one of two readings recorded this
Maternal RBC DHA concentration at baseline
no effect
were not different between the groups at baseline (DHA; 0.86 ± 0.78, Placebo: 0.88 ± 0.71)
PMID:33023067 · one of two readings recorded this
Maternal RBC DHA concentration at delivery
increases, p = 0.001
The maternal RBC DHA concentrations (mol % of fatty acid) (mean ± SD) were not different between the groups at baseline (DHA; 0.86 ± 0.78, Placebo: 0.88 ± 0.71) but significantly higher in the DHA group compared to placebo group at delivery (DHA: 1.94 ± 1.42, Placebo: 0.84 ± 0.56; p < 0.001)
PMID:33023067 · one of two readings recorded this
birth weight
no effect, p = 0.54
There were no significant differences between DHA and placebo groups for mean birth weight (2750.6 ± 421.5 vs. 2768.2 ± 436.6 g, p = 0.54), birth length (47.3 ± 2.0 vs. 47.5 ± 2.0 cm, p = 0.13), or head circumference (33.7 ± 1.4 vs. 33.8 ± 1.4 cm, p = 0.15).
PMID:33668849 · one of two readings recorded this
APGAR score at 1 and 5 minutes
no effect
Not recorded as a finding: No outcome node exists for APGAR score.
The APGAR scores at 1 min and 5 min were similar between the groups.
PMID:33668849 · one of two readings recorded this
birth length
no effect, p = 0.13
There were no significant differences between DHA and placebo groups for mean birth weight (2750.6 ± 421.5 vs. 2768.2 ± 436.6 g, p = 0.54), birth length (47.3 ± 2.0 vs. 47.5 ± 2.0 cm, p = 0.13), or head circumference (33.7 ± 1.4 vs. 33.8 ± 1.4 cm, p = 0.15).
PMID:33668849 · one of two readings recorded this
compliance rate
Compliance was high in both groups (DHA: 88.5% and placebo: 87.1%).
PMID:33668849 · one of two readings recorded this
DHA effect on birth size across subgroups (heterogeneity)
no effect, p = 0.007
The effect of DHA on the birth size (i.e., weight, length, and head circumference) did not differ across any of the subgroups examined (p = 0.007, p-value adjusted for multiplicity using Bonferroni correction).
PMID:33668849 · one of two readings recorded this
gestational age at delivery
no effect, p = 0.54
Gestational age at delivery was similar between DHA and placebo groups (DHA vs. placebo: 38.8 ±1.7 vs. 38.8 ± 1.7 wk, p = 0.54).
PMID:33668849 · one of two readings recorded this
head circumference
no effect, p = 0.15
There were no significant differences between DHA and placebo groups for mean birth weight (2750.6 ± 421.5 vs. 2768.2 ± 436.6 g, p = 0.54), birth length (47.3 ± 2.0 vs. 47.5 ± 2.0 cm, p = 0.13), or head circumference (33.7 ± 1.4 vs. 33.8 ± 1.4 cm, p = 0.15).
PMID:33668849 · one of two readings recorded this
live birth count
There were 450 (94.1%) and 452 (94.3%) live births in the DHA (n = 478) and placebo (n = 479) groups, respectively.
PMID:33668849 · one of two readings recorded this
live birth rate
There were 450 (94.1%) and 452 (94.3%) live births in the DHA (n = 478) and placebo (n = 479) groups, respectively.
PMID:33668849 · one of two readings recorded this
male sex of offspring (count)
There were 230 (52.3%) and 235 (53.4%) male children in the DHA and placebo groups, respectively, and percentages were calculated based on 440 (DHA) and 440 (placebo) analyzed neonates.
PMID:33668849 · one of two readings recorded this
male sex of offspring (rate)
There were 230 (52.3%) and 235 (53.4%) male children in the DHA and placebo groups, respectively, and percentages were calculated based on 440 (DHA) and 440 (placebo) analyzed neonates.
PMID:33668849 · one of two readings recorded this
maternal plasma DHA level change (baseline to delivery)
increases, p = 0.001
There is an increase in mean DHA level in both the groups from baseline to delivery (DHA 1.20 (0.98, 1.43), p = <0.001; placebo 0.24 (0.11, 0.36), p = 0.0002).
PMID:33668849 · one of two readings recorded this
maternal plasma DHA level change (baseline to delivery)
increases, p = 0.0002
There is an increase in mean DHA level in both the groups from baseline to delivery (DHA 1.20 (0.98, 1.43), p = <0.001; placebo 0.24 (0.11, 0.36), p = 0.0002).
PMID:33668849 · one of two readings recorded this
Allocation to control group as predictor of NEC (multivariate CHAID)
decreases, p = 0.002
Multivariate analysis identified that being in the control-group was the strongest predictor for developing NEC (adjusted p = 0.002, Figure 2)
PMID:33671220 · one of two readings recorded this
Apnea in infants older than 29 weeks gestational age as predictor of NEC
increases, p = 0.014
The probability of developing NEC was higher in infants older than 29 weeks of gestational age at birth who presented with apnea (adjusted p = 0.014, Figure 2)
PMID:33671220 · one of two readings recorded this
At least one bleeding entity (IVH grade II or higher, upper GI or pulmonary bleeding)
no effect, p = 0.438
there was no difference between the DHA and control groups in the presence of at least one of the following bleeding entities: periventricular/intraventricular hemorrhage grade ≥ II and upper gastrointestinal tract and/or pulmonary bleeding (68/100 compared with 73/100, p = 0.438)
PMID:33671220 · one of two readings recorded this
Baseline erythrocyte alpha-linolenic acid
increases
The fatty acid profile of erythrocytes collected at the baseline was similar between groups, except that alpha-linolenic acid was higher in the DHA-group (Table 5)
PMID:33671220 · one of two readings recorded this
Confirmed necrotizing enterocolitis (Bell stage IIa or greater)
decreases, p = 0.007
Confirmed NEC was lower in infants from the DHA-group compared with the control-group (0/100 vs. 7/100, p = 0.007) with a RR of 0.93 (95% CI 0.881 to 0.981, p = 0.008)
PMID:33671220 · one of two readings recorded this
Confirmed necrotizing enterocolitis, risk difference
decreases
there was a risk difference of −7% (95% CI −12.00 to −1.99), and a number needed to treat of 15 (95% CI 8.3 to 50)
PMID:33671220 · one of two readings recorded this
Cumulative arachidonic acid intake from human milk
while the control-group received 0.25 (0.12 to 0.38) mg/kg/day and 0.35 (0.18 to 0.63) mg/kg/day, respectively
PMID:33671220 · one of two readings recorded this
Cumulative arachidonic acid intake from human milk
displayed a median of 0.31 (0.12 to 1.13) mg/kg/day and 0.84 (0.35 to 2.52) mg/kg/day in the DHA-group
PMID:33671220 · one of two readings recorded this
Cumulative DHA intake from human milk
while the control-group received 0.25 (0.12 to 0.38) mg/kg/day and 0.35 (0.18 to 0.63) mg/kg/day, respectively
PMID:33671220 · one of two readings recorded this
Cumulative DHA intake from human milk
displayed a median of 0.31 (0.12 to 1.13) mg/kg/day and 0.84 (0.35 to 2.52) mg/kg/day in the DHA-group
PMID:33671220 · one of two readings recorded this
death (per-protocol and intent-to-treat mortality during the study), count
no effect, 3/105 vs 8/109, RR = 0.954 (95% CI 0.896 to 1.015), p = 0.119
Not recorded as a finding: agentless/within-hospital mortality not clearly 'death before discharge' and sentence reports a non-significant RR; no clean two-sided statement for the node
Likewise, in the intent-to-treat analysis, mortality was not different between the DHA-group and control-group (3/105 vs. 8/109, p = 0.119) with an RR = 0.954 for infants in the DHA-group (95% CI 0.896 to 1.015).
PMID:33671220 · one of two readings recorded this
Death
no effect, p = 0.106
The per protocol analysis showed no difference in death between the DHA and control groups (1/100 compared to 5/100, one-sided hypothesis p = 0.106), with an RR of 0.960 for the DHA-group (95% CI 0.914 to 1.008)
PMID:33671220 · one of two readings recorded this
EPA and DHA content of human milk received
decreases
The human milk received by the infants in the DHA-group contained less eicosapentaenoic acid and DHA than the human milk received by the infants in the control-group
PMID:33671220 · one of two readings recorded this
Gestational age as predictor of NEC (multivariate CHAID)
unclear, p = 0.043
Among infants in the control-group, the best predictor for developing NEC was the gestational age (adjusted p = 0.043, Figure 2)
PMID:33671220 · one of two readings recorded this
Median number of bleeding events
no effect, p = 0.814
The median of the bleeding events was similar (1 (1, 2) vs. 1 (1, 2), p = 0.814)
PMID:33671220 · one of two readings recorded this
mortality during the hospital stay, per protocol
no effect, 1/100 vs 5/100, RR 0.960 (95% CI 0.914 to 1.008), p = 0.106
Not recorded as a finding: all-cause-mortality node requires the follow-up horizon recorded with each finding and the sentence names none; the result was also not significant
The per protocol analysis showed no difference in death between the DHA and control groups (1/100 compared to 5/100, one-sided hypothesis p = 0.106), with an RR of 0.960 for the DHA-group (95% CI 0.914 to 1.008).
PMID:33671220 · one of two readings recorded this
Mortality
no effect, p = 0.119
mortality was not different between the DHA-group and control-group (3/105 vs. 8/109, p = 0.119) with an RR = 0.954 for infants in the DHA-group (95% CI 0.896 to 1.015)
PMID:33671220 · one of two readings recorded this
Number needed to treat to prevent one confirmed NEC
there was a risk difference of −7% (95% CI −12.00 to −1.99), and a number needed to treat of 15 (95% CI 8.3 to 50)
PMID:33671220 · one of two readings recorded this
Periventricular/intraventricular hemorrhage grade II or higher
no effect, p = 0.669
Periventricular/intraventricular hemorrhage grade ≥ II was the most common type of bleeding (57% in the DHA-group vs. 54% in the control-group, p = 0.669)
PMID:33671220 · one of two readings recorded this
Platelet count
no effect, p = 0.647
The median (minimum, maximum) of platelet counts was not different between the DHA and control groups at the baseline and after the intervention (196,000 mm3 (107,000, 464,000) vs. 182,000 (103,000, 473,000), p = 0.647 and 345,000 mm3 (120,000, 598,000) vs. 347,000 (131,000, 776,000), p = 0.884, respectively)
PMID:33671220 · one of two readings recorded this
Post-enteral feeding time to diagnosis of confirmed NEC
The post-enteral feeding time to diagnosis of confirmed NEC was 4 (0, 23) days
PMID:33671220 · one of two readings recorded this
Postnatal age at diagnosis of confirmed NEC
The median (minimum, maximum) postnatal age at diagnosis of confirmed NEC was 26 (6, 29) days
PMID:33671220 · one of two readings recorded this
Treatment failure (confirmed NEC or related failure)
decreases, p = 0.031
a lower level of treatment failure in the DHA-group compared with the control-group (6/105 (6%) vs. 16/109 (15%); p = 0.031) with an RR of 0.905 (95% CI 0.826 to 0.991)
PMID:33671220 · one of two readings recorded this
Monocyte ATP-linked oxygen consumption
decreases, p = 0.05
28 days of flaxseed-oil supplementation reduced ATP-linked oxygen consumption (0.75-fold; P < 0.05) and increased spare respiratory capacity (1.4-fold; P < 0.05) in monocytes
PMID:34293124 · one of two readings recorded this
Monocyte spare respiratory capacity
increases, p = 0.05
28 days of flaxseed-oil supplementation reduced ATP-linked oxygen consumption (0.75-fold; P < 0.05) and increased spare respiratory capacity (1.4-fold; P < 0.05) in monocytes
PMID:34293124 · one of two readings recorded this
plasma adiponectin after 28 days of DHA-rich fish oil, versus baseline; the trial's comparison arm was ALA-rich flaxseed oil
increases, 1.1-fold
Not recorded as a finding: the comparison was against another active treatment
Neither supplement altered plasma cytokines; however, adiponectin was increased (1.1-fold; P < 0.05) at the end of the fish-oil phase.
PMID:34293124 · one of two readings recorded this
plasma adiponectin concentration (and plasma oxylipins, cytokines, monocyte bioenergetics) after 4 g/day DHA-rich fish oil versus 4 g/day ALA-rich flaxseed oil, crossover, abstract only
increases, 1.1-fold versus baseline visit
Not recorded as a finding: the comparison was against another active treatment
Neither supplement altered plasma cytokines; however, adiponectin was increased (1.1-fold; P < 0.05) at the end of the fish-oil phase.
PMID:34293124 · one of two readings recorded this
Plasma adiponectin
increases, p = 0.05
adiponectin was increased (1.1-fold; P < 0.05) at the end of the fish-oil phase
PMID:34293124 · one of two readings recorded this
Plasma cytokines
no effect
Neither supplement altered plasma cytokines
PMID:34293124 · one of two readings recorded this
Plasma DHA-derived oxylipins
increases, p = 0.001
there were higher plasma levels of nearly all oxylipins derived from DHA (3.8-fold overall; P < 0.001) and EPA (2.7-fold overall; P < 0.05) after 28 days of fish-oil supplementation
PMID:34293124 · one of two readings recorded this
Plasma EPA-derived oxylipins
increases, p = 0.05
there were higher plasma levels of nearly all oxylipins derived from DHA (3.8-fold overall; P < 0.001) and EPA (2.7-fold overall; P < 0.05) after 28 days of fish-oil supplementation
PMID:34293124 · one of two readings recorded this
Plasma oxylipins
no effect
while there were no changes to oxylipins after flaxseed-oil supplementation
PMID:34293124 · one of two readings recorded this
DHA (and fucoxanthin) productivity of cold-adapted Tisochrysis lutea microalgal culture
decreases, DHA productivity fell 85% (biomass -92%, fucoxanthin -98%) in the original strain when culture temperature was reduced from 30 degC to 15 degC
Not recorded as a finding: the compound is what was measured, not what was given
For the original strain the productivity of biomass, fucoxanthin, and DHA decreased by 92 %, 98 % and 85 % respectively when decreasing the temperature from 30 °C to 15 °C.
PMID:34500104 · one of two readings recorded this
DHA productivity (percentage of biomass) in cultures of the microalga Tisochrysis lutea grown at different temperatures
no effect
Not recorded as a finding: the compound is what was measured, not what was given
In the sorted cold-adapted 'winter strain', biomass, fucoxanthin, and DHA productivities were similar to those at 30 °C.
PMID:34500104 · one of two readings recorded this
Global and subscale cognitive development (Verbal, Perceptual-Performance, Quantitative, Memory, Motor, General Cognitive) on the McCarthy Scales of Children's Abilities (MSCA) at 5 years
no effect, n = 622
Not recorded as a finding: this platform holds no node for the endpoint
There were no significant differences in offspring MSCA scores at 5 years by intervention group (Table 1), and maternal FADS2 SNPs rs174602 or rs174575 were not associated with children’s MSCA scores at 5 years (Table 2).
PMID:34543890 · one of two readings recorded this
MSCA Memory score × FADS2 rs174602 interaction
p = 0.01
We found evidence of an interaction between the intervention and maternal SNP rs174602 in the Quantitative (p=0.02) and Memory scales (p=0.01) of the MSCA test (Table 3).
PMID:34543890 · one of two readings recorded this
MSCA Memory score
increases
Similarly, for Memory scores, among offspring of T homozygotes, those who received the intervention had scored on average 4.3 points higher, which also represents a difference of 0.6 SD.
PMID:34543890 · one of two readings recorded this
MSCA Memory score
increases
Similarly, for Memory scores, among offspring of T homozygotes, those who received the intervention had scored on average 4.3 points higher, which also represents a difference of 0.6 SD.
PMID:34543890 · one of two readings recorded this
MSCA Quantitative score × FADS2 rs174602 interaction
p = 0.02
We found evidence of an interaction between the intervention and maternal SNP rs174602 in the Quantitative (p=0.02) and Memory scales (p=0.01) of the MSCA test (Table 3).
PMID:34543890 · one of two readings recorded this
MSCA Quantitative score
increases
For Quantitative scores, among children whose mothers were homozygotes for the minor allele T, those in the intervention group had on average 3.5 higher scores than those in the control, which is equivalent to a difference of 0.6 SD.
PMID:34543890 · one of two readings recorded this
MSCA Quantitative score
increases
For Quantitative scores, among children whose mothers were homozygotes for the minor allele T, those in the intervention group had on average 3.5 higher scores than those in the control, which is equivalent to a difference of 0.6 SD.
PMID:34543890 · one of two readings recorded this
offspring global cognitive development at 5 years, McCarthy Scales of Children's Abilities (MSCA) scores, by randomised prenatal DHA group
no effect
Not recorded as a finding: this platform holds no node for the endpoint
There were no significant differences in offspring MSCA scores at 5 years by intervention group (Table 1), and maternal FADS2 SNPs rs174602 or rs174575 were not associated with children's MSCA scores at 5 years (Table 2).
PMID:34543890 · one of two readings recorded this

The whole record — 633 rows

Sources cited

9 papers

Subject: all-cis-docosa-4,7,10,13,16,19-hexaenoic acid
Findings: 10
Papers: 9

Other names

15 names

Resolves to: all-cis-docosa-4,7,10,13,16,19-hexaenoic acid

Also called: (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid22:6-4, 7,10,13,16,1922:6(n-3)4,7,10,13,16,19-docosahexaenoic acid4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acidall-cis-4,7,10,13,16,19-docosahexaenoic acidall-cis-DHAC22:6n-3,6,9,12,15,18cervonic acidDHADoconexentDOCOSA-4,7,10,13,16,19-HEXAENOIC ACIDDocosahexaenoic acidFA 22:6
Systematic name: (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid